ANNUAL REPORT 2020 t the Damon Runyon Cancer Research Foundation, we fund A high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave and bold enough to go where others haven’t.

3 A MESSAGE FROM THE

PRESIDENT & CEO Michael and Yadira are just two of the Damon Runyon scientists whose research–and life–was affected by COVID-19. When the extent of the pandemic’s impact on scientific research became evident, the Scientific Committee Now, more than six months later, our scientists of our Board of Directors immediately began report that this support was crucial for enabling discussing how we could support our scientists them to reopen their laboratories and resume at the most critical points of their careers. Thanks their research. For many, returning to full BY ITS NATURE, productivity may take months as the pandemic FOR MANY, continues, but our scientists are undaunted. SCIENCE REQUIRES They have adapted by working in shifts either RESILIENCE. WHEN RETURNING TO FULL early mornings, late nights, or on weekends to maintain social distancing guidelines, and by EXPERIMENTS FAIL OR PRODUCTIVITY MAY meeting with their colleagues and collaborators virtually rather than in person. RESULTS CONFOUND TAKE MONTHS AS THE These are the future leaders in all areas of YUNG S. LIE, PhD EXPECTATIONS, PANDEMIC CONTINUES, cancer research—our mission is to give them the support they need to break past the y its nature, science requires resilience. SCIENTISTS MUST BUT OUR SCIENTISTS barriers and obstacles that lie in their path. We When experiments fail or results are inspired by their fierce determination and confound expectations, scientists must ARE UNDAUNTED. B QUICKLY ADAPT TO resolve to push cancer research forward, no quickly adapt to find a new path forward. matter what challenges they face. FIND A NEW PATH to their proactive leadership and vision, we have The road to becoming a scientist requires no been able to offer an additional investment of less perseverance. Navigating the gauntlet of FORWARD. nearly $1.2 million to our Damon Runyon Fellows graduate school, postdoctoral training, and and Physician-Scientists in the final years of their building an independent research program with cancer but with COVID-19. In this annual award to protect their progress. all present challenges and roadblocks of their report, you’ll hear from Michael W. Drazer, MD, own. Damon Runyon’s awards are intentionally on his experience as a physician during the designed to offer the most promising scientists earliest days of the pandemic, and Yadira M. the resources and support needed to clear Soto-Feliciano, PhD, on how she harnessed the these early career hurdles. resilience and fortitude built up over the course But many of our scientists in this vulnerable of her career to remain productive even while stage of their careers found themselves facing her laboratory was closed. a new and unexpected challenge this spring when the pandemic closed research institutions across the nation. Experiments had to be paused, cell lines frozen, analyses postponed. Physician-scientists had to leave their benches for the frontline, to care for patients not only

4 5 SCIENTIST SPOTLIGHT

YADIRA M. SOTO- FELICIANO, PhD

taught me the importance of OF having good mentors during every stage of your career. We asked Yadira about her The mentality back home was and was accepted to my scientific journey and what to get a job in the industry dream PhD program at the in Puerto Massachusetts Institute of Rico when Technology (MIT). I remember SCIENTIFIC you finished vividly how tough it was from college. But both financial and personal kind of leader she hopes to I made the be in her future laboratory. big decision SOHN FELLOW to take a DISCOVERY DR: TELL US ABOUT job in a bioengineering lab in Boston INSTITUTION YOUR SCIENTIFIC standpoints, but at the end, The JOURNEY, WHICH HAS as a research technician, it really paid off. which felt risky. I was moving PROJECT TITLE COVERED MANY MILES “Dissecting the role of Menin AND REQUIRED SOME thousands of miles away to WHAT KIND OF in acute leukemia” LEAPS OF FAITH. a place where a different LABORATORY language was spoken, to ENVIRONMENT DO YOU YADIRA: One day, a work in a laboratory where I WANT TO CREATE WHEN chemistry professor showed didn’t know anyone! I’m very YOU LEAD YOUR OWN up to my dad’s car painting happy I did that—I learned RESEARCH GROUP? shop in Puerto Rico as a many things, made great client. My dad told him, “Oh, professional relationships, I want to foster an FOLLOWING my daughter just started as a environment in my group that Mutations leading to errors chemistry student in the same will make people comfortable in how DNA stacks inside the university.” This opened the asking questions. It sounds THE chromosome are associated door for me to do research in with many diseases, including his laboratory. Early on, that cancer. Damon Runyon-Sohn Fellow Yadira M. Soto- WINDING Feliciano, PhD, wants to understand this process on a fundamental level to reveal new opportunities to thwart cancer. PATH “I think basic research is critically important, particularly in cancer biology, because it helps us dissect the roots of the problems that cause disease,” she explains.

6 7 SCIENTIST SPOTLIGHT supported by great mentors along the way. I want to use those advantages I’ve had to help other scientists from underrepresented backgrounds. I want them trivial and simple, but the to know that there are these connections have led lab can be an intimidating opportunities in science for to scientifi c collaborations environment. As someone them, there are people who and important discoveries I WANT TO USE [THE] who has faced the challenges look like them, and they in cancer biology and other ADVANTAGES I’VE HAD TO EVEN HAVING ALL THE CARDS STACKED HELP OTHER SCIENTISTS AGAINST ME, I WAS ABLE TO DO IT. FROM UNDERREPRESENTED of building a scientifi c can get to these places fi elds. The Foundation BACKGROUNDS. I WANT career, I am also thinking themselves. also makes an additional of ways to help the next investment in a select group THEM TO KNOW THAT THERE generation of scientists. HOW DOES DAMON of fellows to facilitate the RUNYON transition from postdoctoral ARE OPPORTUNITIES IN PREPARE training to a junior faculty YOU FOR position. CHALLENGING SCIENCE FOR THEM. MOMENTS IN WHAT MOMENT HAVE A SCIENTIFIC YOU BEEN MOST PROUD CAREER? OF AS A DAMON RUNYON FELLOW? Damon Runyon gives us the I think the proudest fi nancial support achievement during my for our salaries fellowship has been writing and research- and submitting a fi rst-author related expenses, manuscript this year when and also provides New York City shut down a wide network due to the pandemic. My of peers, from husband and I live in a one- clinicians to PhDs bedroom apartment with our in different career two-year-old son. Without Even though as a Latina stages, that otherwise would any childcare assistance and woman in science, I’ve not be really hard to reach. In spending only an hour a day had a straightforward path my personal experience, in front of my computer, I was to where I am today, I still able to prepare the fi gures, consider myself privileged write drafts, and email with in the sense that I’ve been collaborators to submit the manuscript. Even having all the cards stacked against me, I was able to do it.

8 9 SCIENTIST SPOTLIGHT

MICHAEL W. DRAZER, MD

SINGLE-MINDED DEDICATION TO UNCOVERING THE GENETIC BASIS OF THE PANDEMIC HAS BLOOD CANCERS EXACERBATED THE

esearchers recently We asked Dr. Drazer to PHYSICIAN-SCIENTIST DAY-TO-DAY UNCERTAINTIES discovered that at discuss the challenges of Cancer Genetics least 13 percent conducting research during R INSTITUTION [...] BUT I’VE STAYED of all blood cancers are a pandemic. The University of Chicago caused by mutations that are FOCUSED ON MY LONG-TERM passed from generation to MICHAEL: I was raised on PROJECT TITLE generation within families. a small family farm in Indiana, “Defi ning leukemogenic mechanisms in hereditary Damon Runyon Physician- and I’ve always been struck RESEARCH GOALS AND hematologic malignancies” Scientist Michael W. Drazer, by how the uncertainty MD, is investigating the of farming mirrors the THE BELIEF THAT THIS WILL cellular mechanisms that give uncertainty of scientifi c rise to these blood cancers research. Both disciplines IMPACT PATIENT LIVES. with the goal of developing require a single-minded earlier diagnostic approaches and therapies.

10 11 SCIENTIST SPOTLIGHT

immunocompromised and cancer syndromes. We more susceptible to the want physicians to realize dedication and an ability to life-threatening effects This irreplaceable collection that this is a problem, so Award is transformational respond to challenges that of the coronavirus. I had of high-tech patient patients aren’t given false because it allows me to look are often beyond our control. to protect those patients “avatars” is, I believe, the reassurances and are offered for those answers even if it When I was in second grade, without compromising the largest of its kind. proper treatments earlier. takes years. The Foundation’s for example, our farm effi cacy of their treatments. This could save lives and leadership is clearly invested fl ooded unexpectedly–my Some interventions, such HOW HAVE YOU improve the care of their in us as people and has been dad and I stayed up all night as stem cell transplants, ADJUSTED YOUR family members. unwavering in its support even digging a trench, trying to are extraordinarily time- APPROACH TO sensitive, so our teams had RESEARCH? during this uncertain time. drain our fi elds and save Now, I am back in the lab at our work for that year. The to be creative in performing 20% of my normal capacity as WHAT IS THE LONG- pandemic has exacerbated those procedures early in I pivoted to answer clinical we maintain social distancing. TERM GOAL FOR YOUR questions and Though we shifted our RESEARCH? turned my research priorities and never WE HAD TO PRESERVE OUR attention to stopped working, we will I hope that my research in bioinformatics still lose months to years of hereditary blood cancers HIGH-TECH PATIENT “AVATARS”: projects which progress during this time. informs the development of can be completed treatments for all types of remotely. For NOVEL, ONE-OF-A-KIND IN WHAT WAYS HAVE blood cancers. I am inspired example, I DAMON RUNYON’S by scientists like Dr. William G. suspected that SUPPORT AND Kaelin, Jr. and my sponsor EXPERIMENTAL MODELS OF many genetic RESOURCES HELPED Dr. Lucy Godley, who have tests incorrectly YOU? used a similar scientifi c PEOPLE WITH THE DIFFERENT evaluated patients philosophy and dedication to for their risk of My patients provide me with develop treatments that are BLOOD CANCERS THAT I STUDY. developing a direct insights into questions saving lives. blood cancer. that inspire my research. The We published a Physician-Scientist Training the day-to-day uncertainties the pandemic when our paper demonstrating that the we always encounter, but healthcare system was majority of these tests are I’ve stayed focused on my already stretched thin. completely inadequate for long-term research goals and our patients with hereditary the belief that this will impact As a physician-scientist, patient lives. I also had to freeze my experiments in the lab as DR: HOW HAVE YOU effi ciently as possible, so BEEN AFFECTED BY I could resume my work at THE COVID-RELATED some point. Damon Runyon SHUTDOWN? has supported my research developing novel, one-of-a- My initial concern was for kind experimental models my patients with blood of people with the different cancers who are often blood cancers that I study.

12 13 A FEW WORDS FROM OUR BOARD MEMBERS

WILLIAM G. KAELIN, JR., MD 2019 Nobel Laureate he fundamental a greater understanding of Vice Chair, Scientific Programs Damon Runyon Board Member “ research that Damon how the SARS-CoV-2 virus T Runyon supports is acts in the human body. By enormously valuable. That supporting young scientists kind of basic research now in basic science that serves as a building relates to cancer research, block for discoveries Damon Runyon generates asic research is an investment in future that apply to nearly all a cadre of scientists breakthroughs. It’s important to point out that “ areas of human health. To who will serve the world one of the reasons things have gone so quickly B use a timely example, well as we increasingly with COVID-19 is the decades of investment in basic scientists who understand face unexpected health understanding of what makes a virus tick. the fundamental challenges that include but We are reaping the benefits of lots of that can be altered in different tumors. mechanisms of stem cells, extend beyond cancer.” knowledge that was accumulated over It’s a fundamentally different and, in many time. Because of basic research, we almost ways, more complex problem despite all inflammatory responses, immediately knew how to sequence the the knowledge we’ve already gathered, we virus, identify the potential , identify still have knowledge to gain. The COVID virology and the immune the likely protein products produced by experience shows that if you have enough those genes, and so on. We were almost knowledge, disseminate the information, system have led the way to limited more by resources than knowledge. and work together, then things can go quite rapidly. In the field of cancer research, That’s where we’d like to get with cancer Damon Runyon is one of the most active —to have enough knowledge so that for forces in building that library of knowledge every single patient’s tumor, we can say and training the researchers who will be ‘We’ve seen this before and we know able to use it.” exactly what to do. We know, for example, ELAINE V. FUCHS, PhD what the altered genes in this tumor do and Former Damon Runyon Fellow how to treat them.’ It’s important to point Damon Runyon Board Member out that for COVID-19, the virus is a 10- problem, as opposed to cancer, which is on the order of 20,000 different genes

14 15 DAMON RUNYON CANCER RESEARCH FOUNDATION Gabrielle Layton, PhD Andrew S. Rachleff Nat Turner PALO ALTO, CALIFORNIA Chairman and Chief Co-Founder and Chief Executive Officer Executive Officer David M. Livingston, MD Wealthfront Inc. Flatiron Health BOARD OF DIRECTORS Emil Frei Distinguished PALO ALTO, CALIFORNIA NEW YORK, NEW YORK Professor of Genetics and Medicine William M. Raveis, Jr. Peter Van Camp VICE CHAIR VICE CHAIR Harvard Medical School Chairman and Chief Executive Chairman Scientific Programs Board Development Dana-Farber Cancer Institute Executive Officer Equinix, Inc. William G. Kaelin, Jr., MD Michael L. Gordon BOSTON, MASSACHUSETTS William Raveis Real Estate, REDWOOD CITY, CALIFORNIA Sidney Farber Professor Chief Executive Officer & Chief Mortgage & Insurance of Medicine Investment Officer David G. Marshall SOUTHPORT, CONNECTICUT James A. Wells, PhD Dana-Farber Cancer Institute Angelo Gordon Chairman and Chief Professor, Department of Executive Officer Pharmaceutical Chemistry and Harvard Medical School NEW YORK, NEW YORK Michael V. Seiden, MD, PhD Investigator, Howard Hughes Amerimar Realty Company President University of California, PHILADELPHIA, PENNSYLVANIA Medical Institute VICE CHAIR The US Oncology Network San Francisco BOSTON, MASSACHUSETTS David M. Beirne THE WOODLANDS, TEXAS SAN FRANCISCO, CALIFORNIA General Partner Richard W. Meier VICE CHAIR X10 Capital Director, The Bakewell Karen D. Seitz Investments and Treasurer SAN FRANCISCO, CALIFORNIA Foundation Founder & Managing Director Yung S. Lie, PhD CHAIR Leon G. Cooperman ST. LOUIS, MISSOURI Fusion Partners Global LLC President and Chief Chairman and Chief VICE CHAIR NEW YORK, NEW YORK Executive Officer Alan M. Leventhal Executive Officer Deborah J. Coleman* John H. Myers Damon Runyon Cancer Chairman and Chief Omega Operating, LLC BOSTON, MASSACHUSETTS President (retired) Nancy Simonian, MD Research Foundation Executive Officer GE Asset Management NEW YORK, NEW YORK Chief Executive Officer Beacon Capital Partners, LLC *Incoming chair FAIRFIELD, CONNECTICUT Syros Pharmaceuticals, Inc. BOSTON, MASSACHUSETTS VICE CHAIR CAMBRIDGE, MASSACHUSETTS Audit and Secretary Richard J. O’Reilly, MD Claire L. Tow Chair in Pediatric Sanford W. Morhouse, Esq. Cynthia F. Sulzberger Oncology Research Of Counsel WELLINGTON, FLORIDA Memorial Sloan Kettering Schulte Roth & Zabel LLP NEW YORK, NEW YORK Cancer Center Judy C. Swanson NEW YORK, NEW YORK HILLSBOROUGH, CALIFORNIA

EMERITUS MEMBERS

Steven J. Burakoff, MD Buck French Scott Greenstein Sidney Altman, PhD I. George Miller, Jr., MD Craig B. Thompson, MD Dean for Cancer Innovation, General Partner President and Chief Content Professor Emeritus of John F. Enders Professor President & CEO, Memorial The Tisch Cancer Institute X10 Capital Officer Molecular, Cellular and of Pediatrics Sloan Kettering Cancer Director, The Tisch Cancer SAN FRANCISCO, CALIFORNIA SiriusXM Developmental Biology Professor of Epidemiology Center Institute - Emeritus NEW YORK, NEW YORK Professor of Chemistry of Molecular Biophysics NEW YORK, NEW YORK Chief, Division of Pediatric Elaine V. Fuchs, PhD Yale University & Biochemistry Hematology and Oncology Laboratory Head, Laboratory Steve Hayden Department of Chemistry Section Chief, Pediatric Virginia Ueberroth Lillian and Henry M. Stratton of Mammalian Cell Biology & Vice Chairman and Chief NEW HAVEN, CONNECTICUT Infectious Diseases Chairman, The Ueberroth Professor of Cancer Medicine Development Creative Officer (retired) Yale School of Public Health Family Foundation Professor of Medicine Rebecca C. Lancefield Ogilvy & Mather Worldwide David Baltimore, PhD NEW HAVEN, CONNECTICUT CORONA DEL MAR, CALIFORNIA Professor of Oncological Professor NEW YORK, NEW YORK President Emeritus Sciences The Rockefeller University Robert Andrews Millikan Henry C. Pitot, MD, PhD Robert C. Wright Icahn School of Medicine at Investigator, Howard Hughes Jay W. Ireland Professor of Biology Professor Emeritus of Senior Advisor, Thomas H. Lee Mount Sinai Medical Institute President and Chief Executive California Institute of Oncology, Pathology and Capital NEW YORK, NEW YORK NEW YORK, NEW YORK Officer (retired) Technology Laboratory Medicine NEW YORK, NEW YORK GE Africa PASADENA, CALIFORNIA McArdle Laboratory for Robyn Coles Richard B. Gaynor, MD SOUTHAMPTON, NEW YORK Cancer Research Robert C. Young, MD President President and Chief of Research Kenneth G. Langone University of Wisconsin- Former Chancellor, Fox Chase TRATE Properties, LLC and Development Morana Jovan-Embiricos, PhD Chairman, President and Madison School of Medicine Cancer Center NEW YORK, NEW YORK BioNTech US Managing Partner Chief Executive Officer and Public Health President , RCY Medicine CAMBRIDGE, MASSACHUSETTS F2 Capital Ventures LLP Invemed Associates, LLC MADISON, WISCONSIN PHILADELPHIA, PENNSYLVANIA Gary E. Erlbaum LONDON, UNITED KINGDOM NEW YORK, NEW YORK President Todd R. Golub, MD Katharine F. Plum Greentree Properties Chief Scientific Officer Steven A. Kandarian Ronald Levy, MD HOBE SOUND, FLORIDA ARDMORE, PENNSYLVANIA and Director, Cancer Program Chairman, President and Chief Professor, Department of Broad Institute of MIT Executive Officer (retired) Medicine Samuel C. Silverstein, MD Thomas J. Fahey, Jr., MD and Harvard MetLife, Inc. Stanford University School Emeritus John C. Dalton Senior Vice President Emeritus Charles A. Dana Investigator NORTH PALM BEACH, FLORIDA of Medicine Professor of Physiology and Memorial Sloan Kettering in Human Cancer Genetics STANFORD, CALIFORNIA Cellular Biophysics Cancer Center Dana-Farber Cancer Institute Noah Knauf Professor of Medicine NEW YORK, NEW YORK Professor of Pediatrics, General Partner Connie Lurie Columbia University College Harvard Medical School Bond Capital ATHERTON, CALIFORNIA of Physicians and Surgeons CAMBRIDGE, MASSACHUSETTS SAN FRANCISCO, CALIFORNIA NEW YORK, NEW YORK

16 17 BAY AREA COMMITTEE AWARD

CO-CHAIR Noah Knauf* Gordon M. Ringold, PhD General Partner Chief Executive Officer PROGRAMS Gabrielle Layton, PhD* Bond Capital Quadriga Biosciences PALO ALTO, CALIFORNIA SAN FRANCISCO, CALIFORNIA LOS ALTOS, CALIFORNIA In FY2020, Damon Runyon awarded nearly CO-CHAIR Brigette Lau Karen D. Seitz* Peter Van Camp* Founding Partner Founder and Managing Director $20M to 71 newly selected, exceptional scientists. Executive Chairman Firework Ventures Fusion Partners Global LLC Equinix, Inc. SAN FRANCISCO, CALIFORNIA NEW YORK, NEW YORK REDWOOD CITY, CALIFORNIA Connie Lurie Judy C. Swanson* DAMON RUNYON FELLOWSHIP AWARD DAMON RUNYON PHYSICIAN- ATHERTON, CALIFORNIA HILLSBOROUGH, CALIFORNIA Ronald A. Castellino, MD Supports the training of the brightest SCIENTIST TRAINING AWARD Professor Emeritus, Radiology, Academic Council Andrew S. Rachleff* Polly Tam postdoctoral scientists as they embark Supports and encourages outstanding Stanford Medicine Chairman and Chief LOS ALTOS HILLS, CALIFORNIA upon their research careers. This funding recent medical school graduates to WOODSIDE, CALIFORNIA Executive Officer Wealthfront Inc. James A. Wells, PhD* enables them to be mentored by established pursue cancer research careers by funding Buck French* PALO ALTO, CALIFORNIA Professor, Department of investigators in leading research laboratories a protected research training experience General Partner Pharmaceutical Chemistry across the country. under the guidance of a highly qualified X10 Capital Isabel Rhee University of California, SAN FRANCISCO, CALIFORNIA LOS ALTOS, CALIFORNIA San Francisco and gifted mentor. SAN FRANCISCO, CALIFORNIA FOUR-YEAR AWARD: $231,000 plus up to $100,000 for medical school loan repayment FOUR-YEAR AWARD: $460,000 plus up to $100,000 for medical school loan repayment *Indicates member is DAMON RUNYON QUANTITATIVE also a Board Member DAMON RUNYON CLINICAL BIOLOGY FELLOWSHIP AWARD INVESTIGATOR AWARD Supports quantitative scientists (trained in fields such as mathematics, computer science, Supports early career physician-scientists NEW YORK METRO COMMITTEE physics, engineering, or related) to pursue conducting patient-oriented research. This research careers in computational biology. innovative program aims to increase the number of physicians who can seamlessly CHAIR Robyn Coles* Joseph R. Osborne, MD, PhD THREE-YEAR AWARD: $240,000 move between the laboratory and the patient’s President Chief, Nuclear Medicine and Karen D. Seitz* bedside in search of breakthrough treatments. TRATE Properties, LLC Molecular Imaging plus up to $100,000 for medical school loan repayment Founder and Managing Director NEW YORK, NEW YORK Director, Molecular Imaging Fusion Partners Global LLC THREE-YEAR AWARD: $600,000 Innovations Institute NEW YORK, NEW YORK DAMON RUNYON-SOHN PEDIATRIC plus up to $100,000 for medical school loan repayment Erica Evans Gioffre Associate Professor, Radiology and the possibility of an additional $400,000 extension Head, Client Engagement New York-Presbyterian CANCER FELLOWSHIP AWARD Kathy Braddock Hirtle, Callaghan & Co. over two years Hospital/Weill Cornell Supports dedicated basic scientists and Managing Director WEST CONSHOHOCKEN, Medicine William Raveis New York City PENNSYLVANIA NEW YORK, NEW YORK clinicians who conduct research with DAMON RUNYON-RACHLEFF NEW YORK, NEW YORK the potential to significantly impact the Gerald M. Marshall Paul Purcell INNOVATION AWARD Melissa L. Cohn Co-Chairman and Chief Managing Director prevention, diagnosis or treatment of President, Melissa Cohn Group Executive Officer William Raveis New York City one or more pediatric cancers. Supports the next generation of exceptionally at Raveis Mortgage Amerimar Enterprises, Inc. NEW YORK, NEW YORK creative thinkers with high-risk, high-reward NEW YORK, NEW YORK President and Chief ideas that have the potential to significantly Executive Officer FOUR-YEAR AWARD: $231,000 Netrality Properties *Indicates member is plus up to $100,000 for medical school loan repayment impact our understanding of and approaches to NEW YORK, NEW YORK also a Board Member the prevention, diagnosis or treatment of cancer. DAMON RUNYON-DALE F. FREY AWARD FOR BREAKTHROUGH SCIENTISTS TWO-YEAR AWARD: $400,000 with the possibility of an additional $400,000 extension Supports a select few Damon Runyon Fellows over two years who have exceeded the Foundation’s highest expectations. This additional investment in these exceptional individuals catapults their research careers and their impact on cancer.

TWO-YEAR AWARD: $100,000

18 Annual Report 2020 19 DAMON RUNYON FELLOWSHIP AWARD COMMITTEE

CHAIR Howard C. Hang, PhD Joel H. Rothman, PhD Jessica Tyler, PhD Matthew G. Vander Heiden, Professor, Immunology and Professor and Wilcox Family Professor, Pathology and MD, PhD Gregory M. Barton, PhD Microbiology and Chemistry Chair in Biotechnology Laboratory Medicine Eisen and Chang Associate Class of ’36 Endowed Chair, The Scripps Research Institute Director, Biomolecular Science Weill Cornell Medicine Professor and Associate Molecular and Cell Biology LA JOLLA, CALIFORNIA and Engineering Program NEW YORK, NEW YORK Director Professor, Immunology University of California, Koch Institute for Integrative and Pathogenesis Jay Hesselberth, PhD Santa Barbara Cancer Research at MIT University of California, Associate Professor, SANTA BARBARA, CALIFORNIA Instructor of Medicine Berkeley Biochemistry and Molecular Dana-Farber Cancer Institute BERKELEY, CALIFORNIA Genetics Susan R. Schwab, PhD and Harvard Medical School University of Colorado Associate Professor, Pathology, VICE CHAIR Member, Broad Institute School of Medicine Skirball Institute of CAMBRIDGE, MASSACHUSETTS E. Jane Albert Hubbard, PhD AURORA, COLORADO Biomolecular Medicine Professor, Cell Biology and New York University School Pathology Susan M. Kaech, PhD of Medicine Skirball Institute of Professor and Director, NOMIS NEW YORK, NEW YORK Biomolecular Medicine Center for Immunobiology and Microbial Studies M. Celeste Simon, PhD New York University DAMON RUNYON School of Medicine NOMIS Chair Arthur H. Rubenstein, MBBCh NEW YORK, NEW YORK Salk Institute for Biological Professor Studies Scientific Director, Abramson Martin D. Burke, MD, PhD LA JOLLA, CALIFORNIA Family Cancer Research May and Ving Lee Professor for Institute FELLOWSHIP AWARD Chemical Innovation Jonathan C. Kagan, PhD Associate Director, Abramson Professor, Chemistry Associate Professor, Pediatrics Cancer Center Core Facilities University of Illinois at Harvard Medical School Department of Cell and Urbana-Champaign Shwachman Chair in Developmental Biology Associate Dean of Research Gastroenterology University of Pennsylvania and Professor Boston Children’s Hospital Perelman School of Medicine BOSTON, MASSACHUSETTS California Salk Institute Yunxiao Zhang, PhD* Carle Illinois College PHILADELPHIA, PENNSYLVANIA Merck Fellow Hokyung K. Chung, PhD of Medicine California Institute of Technology Mechanotransduction in Lynne E. Maquat, PhD Nancy A. Speck, PhD Next generation adoptive cell URBANA, ILLINOIS pathogenesis of osteoarthritis J. Lowell Orbison Endowed Investigator Zibo Chen, PhD* therapy: SMARTER T cells for with Ardem Patapoutian, PhD Jayanta Chaudhuri, PhD Chair Abramson Family Cancer Combinatorial signal enhanced and durable anti- Professor, Immunology Professor, Biochemistry and Research Institute classification with a protein- tumor immunity with Susan M. Program Biophysics Member, Abramson Cancer based synthetic neural network Kaech, PhD Stanford University School of Medicine and with Michael Elowitz, PhD Memorial Sloan Kettering Center Yiming Chen, PhD* Dentistry Cancer Center Member, Institute for Thomas H. Mann, PhD Optical interrogation of Director, Center for Ariana Peck, PhD NEW YORK, NEW YORK Regenerative Medicine Calcium signaling and the neuropeptide and peptide RNA Biology The Mark Foundation for Co-Leader, Hematologic molecular clock of T cell hormones with , Chair of Graduate Women in Malignancies Program, Cancer Research Fellow exhaustion with Susan M. Antonio J. Giraldez, PhD MD, PhD Fergus F. Wallace Professor Science Abramson Cancer Center Expanding the reach of Kaech, PhD Professor and Chair, Cell and structure determination with and Chair, Genetics Ryan A. Flynn, MD, PhD Medical Center Developmental Biology nanocrystal tomography with Yale University School of Scripps Research Institute The interplay between ROCHESTER, NEW YORK University of Pennsylvania Grant J. Jensen, PhD Medicine cellular metabolism and RNA Howard Hughes Medical Perelman School of Medicine Marsha M. Hirschi, PhD Emmanuelle Passegué, PhD homeostasis in disease with Institute Scholar PHILADELPHIA, PENNSYLVANIA Dennis and Marsha Professor, Genetics and Ludwig Institute for Cancer Carolyn R. Bertozzi, PhD NEW HAVEN, CONNECTICUT Research Dammerman Fellow Development Aaron F. Straight, PhD Molecular engineering Director, Columbia Stem Cell Julia Su Zhou Li, PhD* Shuo Han, PhD* Richard I. Gregory, PhD Professor and Chair, of an optically controlled Initiative Spatial regulation of the Fayez Sarofim Fellow Professor, Biological Chemistry Biochemistry glutamate receptor with Columbia University Irving inheritance of genomic Spatiotemporally precise and Molecular Pharmacology, Stanford University Gabriel C. Lander, PhD Medical Center abnormalities in cancer cells manipulation of Hedgehog Department of Pediatrics School of Medicine NEW YORK, NEW YORK with Don W. Cleveland, PhD signaling for tissue Harvard Medical School and STANFORD, CALIFORNIA Haoxin Li, PhD* The Mark Foundation for regeneration and repair with Harvard Stem Cell Institute Philip A. Beachy, PhD Principal Investigator Cancer Research Fellow Boston Children’s Hospital Cysteine-modification BOSTON, MASSACHUSETTS screening to identify functional and druggable sites in cancer dependencies with Benjamin F. Cravatt, PhD

20 21 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

Christina L. Hueschen, PhD Fangfei Qu, PhD University of California, Berkeley Andrew C. Murley, PhD Trang Nguyen, PhD Ziyang Zhang, PhD Molecular basis and regulation Decoding the molecular and HHMI Fellow Bypassing the HHMI Fellow Tess C. Branon, PhD* of apicomplexan parasite cellular mechanisms of the Cell non-autonomous unresponsiveness of T cell Controlling the activity of Robert Black Fellow motility with Alex Dunn, PhD growth of brain metastases communication of ER stress anergy and exhaustion with bispecific T cell engagers with Elucidating mechanisms of with Julien Sage, PhD resistance with Andrew G. Arthur Weiss, MD, PhD a chemically cleavable bidirectional host-microbiota Victoria Hung, PhD Dillin, PhD molecular switch with Kevan M. communication with Gregory Fraternal Order of Jianjin Shi, PhD Tristan Wold Owens, PhD* Shokat, PhD M. Barton, PhD Eagles Fellow Layton Family Fellow Katy Ong, PhD* Suzanne and Bob Wright Defining the post-translational Biochemical and genetic The Mark Foundation for Fellow Xin Zhou, PhD Steven W.M. Crossley, PhD* landscape of ribosomes in dissection of axon Cancer Research Fellow Molecular mechanisms of heat Merck Fellow AGBT - Elaine R. Mardis control of gene regulation and degeneration with Marc Long-range tumor-host shock transcription factor 1 in Understanding and perturbing Fellowship in Cancer cell fate with Maria Barna, PhD Tessier-Lavigne, PhD signaling mechanisms driving cancer with David Agard, PhD protein post-translational Genomics paraneoplastic syndromes with modifications in cancer and Mapping targets for cancer John C. Janetzko, PhD Shaogeng Steven Tang, PhD David Bilder, PhD Cristina Puchades, PhD* autoimmune diseases with therapeutics via Methionine- A biophysical approach to Merck Fellow Deciphering the molecular James A. Wells, PhD selective warheads with studying GRK-GPCR complexes Toward small-molecule Jiao Sima, PhD* basis for modulation of Christopher J. Chang, PhD, and with Brian K. Kobilka, MD inhibitors against human HHMI Fellow TMEM16A activity with Yifan Daniel K. Nomura, PhD Connecticut immune checkpoint PD-1 with Cellular mechanisms linking Cheng, PhD, and Lily Jan, PhD Christopher P. Lapointe, PhD Peter S. Kim, PhD sleep disturbance and cancer Allison Didychuk, PhD Yale University Regulatory roles of the 3’ development with Yang Dan, Sukrit Silas, PhD The Rhee Family Fellow Esen Sefik, PhD untranslated region in human Jing Lin Xie, PhD PhD Discovery and characterization Viral mimics of host HHMI Fellow translation with Joseph D. The Mark Foundation for of virally-encoded proteins of transcription factors in The effect of microbes, diet on Puglisi, PhD Cancer Research Fellow unknown function with Joseph oncogenic herpesviruses with University of California, Los the intestinal immune system Remembering the past: Bondy-Denomy, PhD, and Carol Britt A. Glaunsinger, PhD Angeles in the context of obesity with Chuan Li, PhD epigenetic mechanisms of A. Gross, PhD Christina M. Termini, PhD Richard A. Flavell, PhD Connie and Bob Lurie Fellow cancer drug resistance with Stephanie Gates, PhD Quantifying epistasis between Daniel F. Jarosz, PhD Proteoglycan remodeling Adam J. Stevens, PhD HHMI Fellow of the bone marrow niche Illinois tumor suppressor genes Decoding the ubiquitin receptor Synthetic adhesion molecules: regulates hematopoietic stem and revealing the underlying Leeat Yankielowicz-Keren, recognition mechanism of the redirecting cell infiltration and cell regeneration with John P. University of Illinois at expression profiles at the PhD 26S proteasome with Andreas organization with Wendell A. Chute, MD Urbana-Champaign single-cell level in murine lung Studying the tumor immune Martin, PhD Lim, PhD adenocarcinoma with Dmitri A. microenvironment in breast Daniel J. Blair, PhD Illini 4000 Fellow Petrov, PhD cancer using a novel Jamie Lahvic, PhD University of California, San Diego Kouki Touhara, PhD* An automated small molecule multiplexed imaging platform The Mark Foundation for Robert A. Swanson Family Janice M. Reimer, PhD synthesizer for the discovery Colleen N. McLaughlin, PhD* with Michael R. Angelo, MD, PhD, Cancer Research Fellow Fellow Merck Fellow of new anti-cancer agents with HHMI Fellow and Edgar G. Engleman, PhD Uncovering cell non- Investigating chemical signaling Cell surface mechanisms of Regulation of dynein by Lis1 between gut enteroendocrine Martin D. Burke, MD, PhD autonomous mechanisms of with Andres E. Leschziner, PhD neural circuit assembly with tumor suppression with Iswar cells and intrinsic primary Liqun Luo, PhD afferent neurons with David Maryland K. Hariharan, MBBS, PhD Digvijay Singh, PhD Julius, PhD Cryo-electron tomography of Johns Hopkins School of Medicine phase-separated transcription Linda T. Vo, PhD factories with Elizabeth Xintong Dong, PhD in situ Off-the-shelf T cells from “BEING PART OF THE DAMON RUNYON Villa, PhD Investigating ligand-receptor human pluripotent stem cells interactions between defensins COMMUNITY WAS INSTRUMENTAL TO with precise tumor recognition and mrgprs in cutaneous University of California, using combinatorial antigen- inflammation and wound San Francisco ME GETTING WHERE I AM TODAY. I AM sensing circuits with Jeffrey A. healing with Xinzhong Dong, Vladislav Belyy, PhD Bluestone, PhD PhD THANKFUL FOR THE SUPPORT AT A Mapping the unfolded protein response signaling network Lan Wang, PhD Evan J. Worden, PhD CRITICAL POINT IN MY CAREER.” with optogenetic actuators Conferring organelle-specificity The mechanistic basis of with , PhD to tail-anchored proteins with crosstalk between Peter Walter, PhD H2B ubiquitylation and H3K79 Keelan Z. Guiley, PhD* with Cynthia Yichen Xu, PhD HHMI Fellow Wolberger, PhD DANIEL A. COLÓN-RAMOS, PhD Elucidating the role of ER as Chemical probing of mutant a novel RNA-binding protein p53 with Kevan M. Shokat, PhD Damon Runyon Fellow ‘04-’06 and its function in regulating translation with Davide Yale School of Medicine Ruggero, PhD

22 23 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

National Institutes of Health Broad Institute Erin E. Duffy, PhD* Deepshika Ramanan, PhD Harvard University Massachusetts Institute Activity-dependent changes in National Mah Jongg of Technology Warakorn Pete Kulalert, PhD Matthew H. Bakalar, PhD Grace E. Kenney, PhD RNA stability as a mechanism League Fellow Characterization of the Predicting the interactions of Merck Fellow Lindsay M. LaFave, PhD for synaptic plasticity with Identifying functions of microbiota-mediated cutaneous T cell receptors with peptide- Two enzymatic routes towards Investigating epigenetic Michael E. Greenberg, PhD regulatory T cell subsets neuroimmune interface and its MHC complexes with Nir diazo biosynthesis in cytotoxic mechanisms of transformation in intestinal inflammation impacts on tumorigenesis and Hacohen, PhD natural products with Emily P. in SWI/SNF-mutant non-small Yuan Gao, PhD and colorectal cancer with cancer therapy with Yasmine Balskus, PhD cell lung cancer with Tyler E. HHMI Fellow Christophe Benoist, MD, PhD Belkaid, PhD Veronika Shoba, PhD* Jacks, PhD Mechanism of protein import Phosphorlyation-inducing Thomas R. LaBar, PhD into peroxisomes with Tom A. Jonathan G. Van Vranken, PhD Massachusetts chimeric small molecules with Elucidating the mechanisms Evan C. Lien, PhD Rapoport, PhD The Mark Foundation for Amit Choudhary, PhD, and of cellular evolution with Impact of diet on tumor Cancer Research Fellow Boston Children’s Hospital Stuart L. Schreiber, PhD experimental evolution with metabolism and progression Pragya Goel, PhD* Systematic identification of Andrew W. Murray, PhD with Matthew G. Vander Liudmila Andreeva, PhD Dale F. and Betty Ann Frey metabolite-protein interactions Heiden, MD, PhD Making an inflammasome: Dana-Farber Cancer Institute Fellow in human cells with Steven Monica E. McCallum, PhD Structural and biochemical Signaling structure for Gygi, PhD Phillip A. Dumesic, MD, PhD Understanding alanosine Jon McGinn, PhD* elucidation of NLRP3 neuromodulatory coding in the Identification of muscle- biosynthesis to discover new Dissecting the genetic inflammasome activation vertebrate striatum with Pascal Chuchu Zhang, PhD secreted factors responsible cancer chemotherapeutics with networks underlying host with Hao Wu, PhD Kaeser, MD Molecular dissection of Area for local and systemic effects Emily P. Balskus, PhD subversion during Rickettsia of exercise with Bruce M. Postrema and its role in nausea infection with Rebecca Aaron L. Moye, PhD Rachel S. Greenberg, PhD* with Stephen D. Liberles, PhD Spiegelman, PhD Christopher Wilson, PhD Lamason, PhD, and Michael Role of Lgr6-expressing HHMI Fellow HHMI Fellow Laub, PhD Mesenchymal cells in lung Developing functional diversity Tikvah K. Hayes, PhD Harvard T.H. Chan School Development of a cancer initiation and progression in interoceptive circuits with David M. Livingston, MD, of Public Health programmable writer and Sharanya Sivanand, PhD with Carla F. Kim, PhD Stephen Liberles, PhD Fellow Jeeyun Chung, PhD eraser of m6A RNA methylation Understanding metabolic Systematic genomic and Unraveling the cellular with David R. Liu, PhD heterogeneity in primary Esteban A. Orellana functional analysis of small cell Zhejian Ji, PhD and metastatic tumors with Vinueza, PhD HHMI Fellow mechanism of lipid droplet lung cancer with Matthew L. biogenesis with Tobias C. Matthew G. Vander Heiden, MD, Role of METTL1-WDR4 tRNA Meyerson, MD, PhD Function of the Cdc48 ATPase in Massachusetts General Hospital PhD methyltransferase complex Walther, PhD, and Robert V. protein degradation with Tom A. Kurt J. Warnhoff, PhD in cancer with Richard I. Farese Jr., MD Whitney L. Johnson, PhD Rapoport, PhD Molybdenum cofactor Gregory, PhD Whitehead Institute for HHMI Fellow biosynthetic enzymes Lucy Liu, PhD Mark R. Sullivan, PhD* Biomedical Research Using organoid cancer models Merck Fellow modulate miRNA biology and Yuxiang Zhang, MD, PhD The fat-brain axis: Identifying Laura V. Blanton, PhD to identify genome catastrophe Identifying requirements for development with Gary B. HHMI Fellow the roles of adipokine signaling Lallage Feazel Wall Fellow mechanisms with David S. lung infection by opportunistic Ruvkun, PhD Mechanisms that promote DNA Pellman, MD in nervous system function with The impact of sex chromosome double strand break clusters in pathogens with Eric J. Rubin, Norbert Perrimon, PhD Jingyi Wu, PhD constitution on immune cell brain and liver with MD, PhD Jasper E. Neggers, PhD Epigenetic clonal evolution in gene expression and function Frederick W. Alt, PhD Validation of VPS4A as a Nagarajan Nandagopal, PhD gliomas with Bradley Bernstein, with David C. Page, MD synthetic lethal target in Philip O’Bryan Montgomery, MD, PhD Ge Zheng, PhD cancers with VPS4B loss on Jr., MD, Fellow HHMI Fellow chromosome 18q with Andrew Signal integration by bHLH Novel approaches to targeting J. Aguirre, MD, PhD, and circuits to enable cell fate zinc-finger domain of the Todd R. Golub, MD decisions with Galit Lahav, PhD, transcription repressor BCL11A and Sean Megason, PhD “CANCER PATIENTS NEED with Stuart Orkin, MD Harvard Medical School Nikit B. Patel, PhD* INVESTIGATORS TO TAKE THESE Determining the core genetic Brigham and Women’s Hospital Amelia N. Chang, PhD RISKS—THEY CANNOT WAIT FOR The role of activity-regulated regulators of the erythro- Kunitoshi Chiba, PhD gene expression in human myeloid switch with Allon Klein, THE CURES TO BECOME OBVIOUS.” William Raveis Charitable Fund brain evolution with Michael E. PhD Fellow Greenberg, PhD The role of a tumor suppressor Sarah J. Pfau, PhD gene ASXL1 in immune evasion Anne E. Dodson, PhD Investigating the molecular during tumorigenesis with CHRISTIN E. BURD, PhD Transgenerational inheritance determinants of blood-brain Stephen J. Elledge, PhD barrier heterogeneity with of structure-based infections Damon Runyon-Rachleff Innovator ‘16-’19 with Scott G. Kennedy, PhD Chenghua Gu, PhD The Ohio State University

24 25 DAMON RUNYON FELLOWSHIP AWARD CONTINUED

Elizabeth A. Costa, PhD Andrew A. Bridges, PhD New York University Juhee Pae, PhD University of Pittsburgh Canada Robert Black Fellow HHMI Fellow Berger Foundation Fellow Sophia C. Tintori, PhD Abigail E. Overacre-Delgoffe, Exploring the cell adhesion Bacterial cell fates: The role Mechanisms of germinal center University of Calgary Mechanisms of radiation PhD landscape through host- of quorum sensing in biofilm B Cell proliferation with Gabriel tolerance in Caenorhabditis Microbiome control of Ysbrand Nusse, PhD* pathogen interactions with patterning with Bonnie L. D. Victora, PhD from Chernobyl with Matthew the tumor microenvironment: Robert Black Fellow Sebastian Lourido, PhD Bassler, PhD Rockman, PhD harnessing immunosuppression Defining the role of eosinophils John C. Zinder, PhD and exhaustion with Timothy W. in liver injury and repair with Daniel H. Lin, PhD Antony J. Burton, PhD Lorraine W. Egan Fellow Hand, PhD, and Olivera Paul Kubes, PhD HHMI Fellow Sculpting New York University Structure and biochemistry of Finn, PhD The influence of RNA and architecture in live cells School of Medicine human and associated *Initial Year protein conformation on target- using protein chemistry factors with , PhD Nicholas M. Adams, PhD* Utah § Physician-Scientists directed miRNA degradation with Tom W. Muir, PhD Marion Abbe Fellow with David P. Bartel, PhD Elucidating how pDC genome Weill Cornell Medicine University of Utah School Courtney Ellison, PhD* organization regulates IFN of Medicine Jingchuan Luo, PhD* The role of type IV pili in production in cancer with Eric E. Gardner, PharmD, PhD HHMI Fellow Pseudomonas aeruginosa Boris Reizis, PhD Kenneth G. and Elaine A. Lexy von Diezmann, PhD Deciphering roles of nuclear- biofilm formation with Joshua Langone Fellow The Mark Foundation for Cancer Research Fellow mitochondrial communication Shaevitz, PhD, and Zemer Robert S. Banh, PhD Interrogating lung State changes of a liquid- in cellular homeostasis with Gitai, PhD Merck Fellow adenocarcinoma like compartment monitor Jonathan S. Weissman, PhD Metabolic contribution transformation to small cell crossover recombination New York of sensory neurons, via lung cancer at single cell with Ofer Rog, PhD, and Erik Alexandra Nguyen, PhD peripheral axons, to pancreatic resolution with Harold E. Jorgensen, PhD Defining the cell type specific Columbia University tumorigenesis and serine Varmus, MD cell division requirements in J. Brooks Crickard, PhD metabolism with Alec acute myeloid leukemias with Oregon Washington The Mark Foundation for Kimmelman, MD, PhD, and Iain M. Cheeseman, PhD Cancer Research Fellow Michael Pacold, MD, PhD Oregon Health & Science University Fred Hutchinson Cancer Visualizing the strand Dian Yang, PhD Research Center invasion during homologous Yunsik Kang, PhD Dissecting intratumoral The Rockefeller University recombination on the single Molecular mechanisms Tyler Starr, PhD heterogeneity and hierarchy molecule level with Eric C. Aleksey Chudnovskiy, PhD regulating phagocytosis HHMI Fellow at single cell resolution with Greene, PhD Defining dendritic cell-T cell of neurons with Marc R. The sequence-function Jonathan S. Weissman, PhD, interaction history within the Freeman, PhD landscape of antibody affinity and Trever G. Bivona, MD, PhD tumor microenvironment using maturation with Jesse D. Memorial Sloan Kettering enzymatic labeling with Gabriel Pennsylvania Bloom, PhD, and Frederick Missouri Cancer Center D. Victora, PhD Matsen, PhD Kaixian Liu, PhD* University of Pennsylvania Washington University The studies of double-strand Gregory P. Donaldson, PhD Geoffrey P. Dann, PhD University of Washington Darryl A. Wesener, PhD break proteins in germline Robert Black Fellow Merck Fellow Synthetic food particles for genome transmission with Cross-talk between B Junhong Choi, PhD* Proteomics to bridge protein studying human gut microbiota Scott N. Keeney, PhD, and lymphocytes and bacteria HHMI Fellow in the maintenance of a arginylation, chromatin, and Determinants and function with Jeffrey I. Gordon, MD Shixin Liu, PhD non-inflammatory mucosal cancer with Benjamin A. consequences of DNA Ryan H. Moy, MD, PhD*§ microbiome with Daniel Garcia, PhD replication program with Jay A. New Jersey Robert Black Fellow Mucida, PhD Shendure, MD, PhD Balint Z. Kacsoh, PhD* Princeton University Identifying the key drivers and mechanisms underlying Anita Gola, PhD* Rebecca Ridley Kry Fellow Caroline Bartman, PhD metastatic liver colonization in A spatially patterned stem Influence of social environment The Mark Foundation for colorectal cancer with Sohail cell and immune cell barrier at on cancer progression with Cancer Research Fellow Tavazoie, MD, PhD the skin surface with Elaine V. Shelley Berger, PhD, and Systems analysis of in vivo Fuchs, PhD Christopher J. Lengner, PhD tumor and stromal cell Jose Reyes, PhD metabolism in pancreatic HHMI Fellow Yusong R. Guo, PhD Romain L. Riscal, PhD ductal adenocarcinoma with Dynamics and impact of HHMI Fellow Exploiting Cholesterol Joshua Rabinowitz, MD, PhD genetic and non-genetic Structural and mechanistic metabolism as a liability in diversification driven by loss of characterization of clear cell Renal Cell Carcinoma p53 with Scott Lowe, PhD, and mechanosensitive Piezo (ccRCC) with M. Celeste Dana Pe’er, PhD channels with Roderick Simon, PhD MacKinnon, MD

26 27 DAMON RUNYON DAMON RUNYON QUANTITATIVE BIOLOGY QUANTITATIVE BIOLOGY FELLOWSHIP AWARD COMMITTEE FELLOWSHIP AWARD

Aviv Regev, PhD X. Shirley Liu, PhD Caroline Uhler, PhD California Oregon Vermont Executive Vice President and Professor, Data Science Henry L. and Grace Doherty Vitor Mori, PhD* Head, Research and Early Director, Center for Functional Associate Professor Hang Xu, PhD* Jeremy Copperman, PhD* EBUS-TBNI of cisplatin Development Cancer Epigenetics Department of Electrical Investigating the dynamics Whole-cell modeling for optimization in heterogeneous Genentech, Inc. Dana-Farber Cancer Institute Engineering and Computer of chromosomal instability in the prediction and control lung tumors with Jason H.T. SOUTH SAN FRANCISCO, CALIFORNIA Harvard University Science cancer with Christina N. Curtis, of micro-environmentally Bates, PhD, DSc, and C. BOSTON, MASSACHUSETTS Institute for Data, Systems and PhD, and Calvin Kuo, PhD, regulated proliferative and Matthew Kinsey, MD, University Andrea Califano, PhD Society Stanford University School of migratory variability with of Vermont, Burlington Chair, Systems Biology Lior Pachter, PhD Massachusetts Institute of Medicine, Stanford Daniel M. Zuckerman, PhD, Irving Cancer Research Center Bren Professor of Technology and Joe W. Gray, PhD, Oregon Columbia University Computational Biology CAMBRIDGE, MASSACHUSETTS Massachusetts Health and Science University, Washington NEW YORK, NEW YORK Departments of Biology and Portland Computing/Mathematical Ad Hoc Member Denis Schapiro, PhD* Tal Einav, PhD* Anshul Kundaje, PhD Quantifying a polyclonal Sciences Todd R. Golub, MD Single cell pharmacodynamics Assistant Professor, Genetics Texas immune repertoire’s ability California Institute of Director, Cancer Program and spatial signatures of drug and Computer Science to bind influenza with Jesse Technology Chief Scientific Officer response in the intact tumor Runmin Wei, PhD* Stanford University D. Bloom, PhD, and Jonathan PASADENA, CALIFORNIA The Broad Institute of MIT and microenvironment with Aviv Integrating single cell genomic STANFORD, CALIFORNIA W. Yewdell, MD, PhD, Fred Harvard Regev, PhD, and Peter K. and spatial information to Dana Pe’er, PhD Sorger, PhD, Harvard Medical delineate tumor heterogeneity Hutchinson Cancer Research Howard Hughes Medical Center, Seattle Chair, Computational and Institute Investigator School, Boston and microenvironment Systems Biology Program CAMBRIDGE, MASSACHUSETTS interactions in inflammatory Scientific Director, Metastasis Collin Tokheim, PhD* breast cancer with Nicholas E. and Tumor Ecosystems Center Computationally identifying Navin, PhD, and Ken Chen, *Initial Year Sloan Kettering Institute oncogenic substrates of the PhD, University of Texas MD Memorial Sloan Kettering ubiquitin-proteasome system in Anderson Cancer Center, Cancer Center human cancers with X. Shirley Houston NEW YORK, NEW YORK Liu, PhD, and Eric S. Fischer, PhD, Dana-Farber Cancer Institute, Boston

Shou-Wen Wang, PhD* Inferring cell fate choice from “I BUILT PERSONAL RELATIONSHIPS WITH clonal and transcriptomic data, with application to THE FOUNDATION, SCIENTIFIC COMMITTEE hematopoiesis with Allon M. Klein, PhD, and Fernando MEMBERS, AND OTHER AWARDEES, WHICH Camargo, PhD, Harvard Medical I FORESEE BEING LONG-LASTING AND School, Boston LEADING TO FRUITFUL AND FEARLESS New York Siting Gan, PhD* COLLABORATIONS.” In situ single-cell dissection of the tumor-microenvironment interplay mediating brain GIADA BIANCHI, MD metastasis with Joan Massagué, PhD, and Dana Pe’er, PhD, Damon Runyon Physician-Scientist ‘16-’19 Memorial Sloan Kettering Cancer Center, New York Dana-Farber Cancer Institute and Harvard Medical School

28 29 DAMON RUNYON-SOHN DAMON RUNYON-SOHN PEDIATRIC CANCER FELLOWSHIP PEDIATRIC CANCER AWARD COMMITTEE FELLOWSHIP AWARD

CHAIR Patrick A. Brown, MD Adolfo A. Ferrando, MD, PhD California New York Washington Director, Pediatric Leukemia Professor, Pediatrics and Andrew L. Kung, MD, PhD Zulekha A. Qadeer, PhD Jessie A. Brown, PhD Kiara C. Eldred, PhD* Associate Professor, Oncology Pathology Chair and Professor, Pediatrics Targeting TGF pathway Candy and William Raveis Dissecting the mechanisms of Assistant Professor, Pediatrics Institute for Cancer Genetics β Memorial Sloan Kettering dependencies in Group 3 Fellow tumorigenesis in the human Johns Hopkins School Columbia University Medical Cancer Center Medulloblastoma with William Master regulators of drug retina with Thomas Reh, PhD, of Medicine Center NEW YORK, NEW YORK A. Weiss, MD, PhD, University resistance in relapsed acute University of Washington, BALTIMORE, MARYLAND NEW YORK, NEW YORK of California, San Francisco lymphoblastic leukemia with Seattle Scott A. Armstrong, MD, PhD Peter D. Cole, MD Lee J. Helman, MD Adolfo A. Ferrando, MD, PhD, President, Dana-Farber/Boston Professor, Pediatrics Professor, Pediatrics and Kathryn R. Taylor, PhD Columbia University Medical Jay F. Sarthy, MD, PhD§ Children’s Cancer and Blood Chief, Division of Pediatric Medicine The effect of neuronal activity Center, New York Characterization of the Disorders Center Hematology/Oncology Keck School of Medicine on pediatric glioma invasion epigenomic landscape of Chair, Pediatric Oncology Embrace Kids Foundation Chair University of Southern with Michelle L. Monje, MD, Srinjoy Chakraborti, PhD diffuse midline gliomas with Dana-Farber Cancer Institute in Pediatric Hematology/ California PhD, Stanford University School Mining pHLA and T cell Steven Henikoff, PhD, Fred David G. Nathan Professor Oncology Head, Basic and Translational of Medicine, Stanford receptor (TCR) specificities by Hutchinson Cancer Research of Pediatrics Rutgers Cancer Institute of Research, Children’s Center phage display for de novo TCR Center, Seattle Harvard Medical School Peng Wu, MD, PhD§ New Jersey for Cancer and Blood Diseases engineering and personalized Associate Chief of the Division Understanding and modulating Robert Wood Johnson Children’s Hospital Los Angeles cancer therapy with Jonathan R. *Initial Year of Hematology/Oncology aberrant differentiation in Lai, PhD, Albert Einstein § Physician-Scientists Medical School LOS ANGELES, CALIFORNIA Boston Children’s Hospital hepatoblastoma with Roeland Rutgers, The State University College of Medicine, Bronx BOSTON, MASSACHUSETTS Nusse, PhD, Stanford University of New Jersey Agata Smogorzewska, MD, PhD School of Medicine, Stanford NEW BRUNSWICK, NEW JERSEY Associate Professor and Head Marissa Rashkovan, PhD Julia Glade Bender, MD Laboratory of Genome Targeting metabolic Vice Chair for Clinical Research Maintenance Massachusetts vulnerabilities in ETP-ALL with Adolfo A. Ferrando, MD, PhD, Department of Pediatrics The Rockefeller University Adam D. Durbin, MD, PhD§ Columbia University Medical Memorial Sloan Kettering NEW YORK, NEW YORK Interrogation of neuroblastoma Center, New York Cancer Center dependencies and non-coding NEW YORK, NEW YORK on the core-regulatory Yadira M. Soto-Feliciano, PhD circuitry for therapeutic Dissecting the role of Menin in inhibition with A. Thomas acute leukemia with C. David Look, MD, Dana-Farber Cancer Allis, PhD, The Rockefeller Institute, Boston “I AM THANKFUL TO ALL THE BRILLIANT University, New York STUDENTS AND COLLEAGUES I HAVE Sarah Naomi Olsen, PhD Targeted degradation of the Tennessee WORKED WITH AND THE AMAZING MLL-AF9 fusion oncoptrotein Katherine E. Gadek, PhD in acute myeloid leukemia with Defining endothelial SUPPORT, LIKE THE DAMON RUNYON, Scott A. Armstrong, MD, PhD, progenitor cell pliancy in Dana-Farber Cancer Institute, rhabdomyosarcoma with Mark I HAVE RECEIVED THROUGHOUT MY Boston Hatley, MD, PhD, and Stacey Ogden, PhD, St. Jude Children’s Maxim Pimkin, MD, PhD§ Research Hospital, Memphis CAREER. IT MOTIVATES ME TO PAY IT Divergent core transcriptional FORWARD.” circuitries highlight context- Anand G. Patel, MD, PhD*§ specific vulnerabilities in AML Targeting the developmental with Stuart H. Orkin, MD, Dana- architecture of Farber Cancer Institute, Boston rhabdomyosarcoma with Michael A. Dyer, PhD, St. Jude PARDIS C. SABETI, MD, DPhil Children’s Research Hospital, Memphis Damon Runyon Fellow ‘04-’06

Harvard University and the Broad Institute

30 31 DAMON RUNYON DAMON RUNYON DALE F. FREY AWARD FOR PHYSICIAN-SCIENTIST TRAINING BREAKTHROUGH SCIENTISTS AWARD COMMITTEE

Lindsay B. Case, PhD* Natasha M. O’Brown, PhD* Iva A. Tchasovnikarova, PhD* CHAIR Lucy A. Godley, MD, PhD David R. Piwnica-Worms, MD, Regulation of integrin Molecular and cellular CRIS Cancer Foundation Co-Director, Center for PhD William G. Kaelin, Jr., MD clustering on supported lipid mechanisms of transcytosis Breakthrough Scientist Clinical Cancer Genetics Professor and Chair, Cancer Sidney Farber Professor bilayers at University of Texas regulation in blood-brain Fluorogenetic interrogation Hospira Foundation Professor Systems Imaging of Medicine Southwestern Medical Center, barrier function at Harvard of chromatin position effects of Medicine and Human Deputy Division Head, Dana-Farber Cancer Institute Dallas Medical School, Boston at The Gurdon Institute at Genetics Department of Research and Harvard Medical School the University of Cambridge, Section of Hematology and Affairs, Division Howard Hughes Medical Ivana Gasic, Dr.Sc.* Benjamin M. Stinson, PhD* Cambridge Oncology of Diagnostic Imaging Institute Investigator CRIS Cancer Foundation Mechanism of DNA processing The University of Chicago The University of Texas MD BOSTON, MASSACHUSETTS Breakthrough Scientist during non-homologous end Yi Yin, PhD* Medicine Anderson Cancer Center joining at Harvard Medical Global analysis of DNA break CHICAGO, ILLINOIS HOUSTON, TEXAS Molecular elucidation of David P. Carbone, MD, PhD School, Boston repair by single-cell sequencing the interphase Microtubule Barbara J. Bonner Chair in at University of California, Los Peter S. Nelson, MD Kornelia Polyak, MD, PhD Integrity Response (MIR) at Lung Cancer Research University of Geneva, Geneva Angeles Member, Divisions of Human Professor of Medicine, Director, James Thoracic Biology, Clinical Research and Department of Medical Center *Initial Year Public Health Sciences Oncology Professor, Division of Medical Endowed Chair for Prostate Dana-Farber Cancer Institute Oncology Cancer Research and Harvard Medical School Comprehensive Cancer Center Fred Hutchison Cancer BOSTON, MASSACHUSETTS The Ohio State University Research Center COLUMBUS, OHIO Professor, Division of Medical Cassian Yee, MD Oncology Professor, Melanoma Adjunct Professor, Genome Medical Oncology Sciences and Pathology Professor, Immunology University of Washington Division of Cancer Medicine School of Medicine Director, Department of Solid SEATTLE, WASHINGTON Tumor Cell Therapy Center for Cancer Immunology “DAMON RUNYON’S MODEL OF SUPPORTING Research The University of Texas MD OUTSTANDING YOUNG SCIENTISTS ACROSS DIVERSE Anderson Cancer Center HOUSTON, TEXAS FIELDS OF STUDY IS INCREDIBLY SUCCESSFUL DAMON RUNYON BECAUSE YOU CAN’T TELL WHERE THE NEXT BIG IDEA OR OPPORTUNITY WILL ORIGINATE.” PHYSICIAN-SCIENTIST TRAINING AWARD

THOMAS M. NORMAN, PhD

Damon Runyon Fellow ‘15-’18 California Maryland Massachusetts Damon Runyon-Dale F. Frey Breakthrough Jennifer L. Caswell-Jin, MD Jonathan C. Dudley, MD* Elisa A. Aquilanti, MD* Scientist ‘20-’22 Breast cancer evolution and Gordon Family Physician- The Ben and Catherine Ivy resistance in response to HER2- Scientist Foundation Physician-Scientist Memorial Sloan Kettering Cancer Center targeted therapy with Christina Earlier detection of cancer Targeting telomerase in N. Curtis, PhD, and Allison W. in body cavity fluids through glioblastoma with Matthew Kurian, MD, Stanford University aneuploidy analysis after cell L. Meyerson, MD, PhD, Dana- School of Medicine, Stanford enrichment and partitioning Farber Cancer Institute, Boston with , MD, Andrew L. Ji, MD* The Johns Hopkins University Edmond M. Chan, MD Cancer cell-extrinsic and School of Medicine, Baltimore Validating a novel synthetic intrinsic control of tumor lethal target for microsatellite progression and intratumoral unstable cancers with Adam J. heterogeneity with Paul A. Bass, MD, Dana-Farber Cancer Khavari, MD, PhD, Stanford Institute, Boston University School of Medicine, Stanford

32 33 DAMON RUNYON PHYSICIAN-SCIENTIST TRAINING AWARD CONTINUED DAMON RUNYON CLINICAL INVESTIGATOR AWARD COMMITTEE

Christopher J. Gibson, MD Natalie Vokes, MD* Melody Smith, MD CHAIR Daniel F. Hayes, MD, FACP, FASCO Kwok-Kin Wong, MD, PhD The biology and clinical The Mark Foundation for CD19 targeted donor T cells Stuart B. Padnos Professor Anne Murnick Cogan and Charles L. Sawyers, MD implications of clonal Cancer Research Physician- improve graft versus tumor of Breast Cancer Research David H. Cogan Professor Chair, Human Oncology hematopoiesis in cancer Scientist activity and reduce graft Clinical Director, Breast of Oncology, Department and Pathogenesis Program patients with Benjamin L. Ebert, Dissecting tumor intrinsic and versus host disease with Marcel Oncology Program of Medicine Marie-Josée and MD, PhD, Dana-Farber Cancer immune drivers of resistance R.M. van den Brink, MD, PhD, University of Michigan Rogel Director, Division of Henry R. Kravis Chair, Human Institute, Boston to therapy in non-small cell Memorial Sloan Kettering Cancer Center Hematology and Medical Oncology and Pathogenesis lung cancer with Eliezer M. Van Cancer Center, New York ANN ARBOR, MICHIGAN Oncology Memorial Sloan Kettering Gabriel K. Griffin, MD Allen, MD, Dana-Farber Cancer Laura and Isaac Perlmutter Cancer Center Enhancing cancer Institute, Boston Rabi Upadhyay, MD Andrew L. Kung, MD, PhD Cancer Center Howard Hughes Medical immunotherapy through Determining the distal effects Professor and Chair, Pediatrics NYU Langone Health Institute Investigator epigenetic modulation of of gut microbiota on the lung Memorial Sloan Kettering NEW YORK, NEW YORK New York NEW YORK, NEW YORK the repetitive genome with tumor microenvironment, Cancer Center Andrew J. Dunbar, MD NEW YORK, NEW YORK Bradley E. Bernstein, MD, PhD, cancer progression, and Karla V. Ballman, PhD Sandra L. Wong, MD, MS and Arlene H. Sharpe, MD, Interrogating functional checkpoint blockade efficacy Chair and William N. and Bessie contribution of JAK2V617F Chief, Division of Biostatistics Ramon E. Parsons, MD, PhD PhD, Brigham and Women’s with Dan R. Littman, MD, PhD, and Epidemiology Allyn Professor of Surgery Hospital, Boston in the maintenance of New York University School Director, Tisch Cancer Institute Senior Vice President, Surgical myeloproliferative neoplasms Professor, Healthcare Policy Ward-Coleman Chair in of Medicine, New York and Research Service Line Lillian M. Guenther, MD with Ross L. Levine, MD, Cancer Research Dartmouth-Hitchcock Medical Memorial Sloan Kettering Weill Cornell Medicine Director, Mount Sinai Cancer William Raveis Charitable North Carolina NEW YORK, NEW YORK Center Fund Physician-Scientist Cancer Center, New York and Mount Sinai Health The Geisel School of Medicine Nicholas C. DeVito, MD System Investigation of CITED2 as a Howard A. Fine, MD at Dartmouth John R. Ferrarone, MD Investigating the role of Professor and Chair, novel dependency in Ewing Director, Brain Tumor Center LEBANON, NEW HAMPSHIRE Lee Cooperman EMT-mediated dendritic cell Oncological Sciences sarcoma with Kimberly Associate Director, Physician-Scientist tolerization in checkpoint Icahn School of Medicine Stegmaier, MD, Dana-Farber Translational Research, Founding Member Seeking and evaluating novel inhibitor resistance with Brent at Mount Sinai Cancer Institute, Boston Sandra and Edward Meyer therapeutic targets in human A. Hanks, MD, PhD, Duke NEW YORK, NEW YORK Richard J. O’Reilly, MD lung adenocarcinomas with University, Durham Cancer Center Claire L. Tow Chair in Pediatric Harshabad Singh, MBBS Louis and Gertrude Feil loss-of-function mutations in Jedd D. Wolchok, MD, PhD Oncology Research Cellular origins of Barrett’s Professor of Medicine LKB1 with Harold E. Varmus, Ohio Lloyd J. Old/Virginia and Daniel Chief, Pediatric Bone Marrow esophagus and its role Chief, Division of MD, Weill Cornell Medicine, K. Ludwig Chair in Clinical Transplant Service in development of Jonathan E. Shoag, MD Neuro-Oncology New York Investigation Memorial Sloan Kettering adenocarcinoma with Ramesh Harnessing clinical data to New York-Presbyterian/Weill Chief, Immuno-Oncology Cancer Center A. Shivdasani, MD, PhD, Dana- identify new prostate cancer Cornell Medicine Farber Cancer Institute, Boston Dennis J. Hsu, MD* Service NEW YORK, NEW YORK therapeutics with Christopher NEW YORK, NEW YORK Metabolic determinants of Director, Parker Institute for E. Barbieri, MD, PhD, University codon usage bias in colorectal Cancer Immunotherapy Sakiko Suzuki, MD Hospitals Cleveland Medical cancer with Sohail F. Tavazoie, Associate Director, Ludwig Inflammatory cell death Center, Cleveland pathways in Myelodysplastic MD, PhD, Memorial Sloan Center for Cancer Kettering Cancer Center/The Immunotherapy Syndromes with Michelle A. *Initial Year Kelliher, PhD, and Peter E. Rockefeller University, New Memorial Sloan Kettering Newburger, MD, University of York Cancer Center Massachusetts Medical School, NEW YORK, NEW YORK Worcester

34 35 DAMON RUNYON CLINICAL INVESTIGATOR AWARD

California Massachusetts Matthew D. Hellmann, MD North Carolina Jennifer M. Kalish, MD, PhD David G. McFadden, MD, PhD Defining intratumoral and Epigenetic and genetic Identifying metabolic Collin M. Blakely, MD, PhD Birgit Knoechel, MD, PhD* Yvonne M. Mowery, MD, PhD* peripheral mechanisms mechanisms of cancer vulnerabilities in Hürthle Doris Duke-Damon Runyon Mechanisms of CD8+ T-cell Evaluating and targeting mediating initiation of in Beckwith-Wiedemann cell carcinoma with Steven Clinical Investigator dysfunction and its therapeutic pathways of treatment response, durability, Syndrome with Marisa S. L. McKnight, PhD, and Mechanisms of incomplete targeting in T-ALL with resistance in head and neck and resistance to PD-1 Bartolomei, PhD, and Garrett Ralph J. DeBerardinis, MD, response and primary Kimberly Stegmaier, MD, and squamous cell carcinoma with blockade to inform rational A. Brodeur, MD, Children’s PhD, University of Texas resistance to osimertinib in Catherine J. Wu, MD, David G. Kirsch, MD, PhD, Duke immunotherapeutic Hospital of Philadelphia, Southwestern Medical Center, EGFR-mutant lung cancer with Dana-Farber Cancer Institute, University, Durham development in NSCLC with Philadelphia Dallas Trever G. Bivona, MD, PhD, Boston Charles M. Rudin, MD, PhD, Pennsylvania University of California, Texas and Jedd D. Wolchok, MD, *Initial Year San Francisco Matthew G. Oser, MD, PhD Brian C. Capell, MD, PhD PhD, Memorial Sloan Kettering Todd A. Aguilera, MD, PhD* Targeting neuroendocrine Defining the role of epigenetic Cancer Center, New York Immunologic responses to Anusha Kalbasi, MD* differentiation as a novel enhancer dysfunction in short course radiotherapy in IL13Ra2 Chimeric Antigen therapeutic strategy for small epithelial carcinogenesis Andrew M. Intlekofer, MD, PhD rectal adenocarcinoma and Receptor (CAR) T cells for cell lung cancer with William G. with Shelley L. Berger, PhD, Metabolic coupling of the the impact of CD40 agonist metastatic melanoma with Kaelin, Jr., MD, Dana-Farber University of Pennsylvania, hypoxic niche to stemness with immunotherapy with Robert D. Antoni Ribas, MD, PhD, Cancer Institute, Boston Philadelphia Ross L. Levine, MD, Memorial Timmerman, MD, and Yang- and Christine Brown, PhD, Sloan Kettering Cancer Center, Xin Fu, MD, PhD, University of University of California, Los New York Texas Southwestern Medical Angeles New York Center, Dallas Karuna Ganesh, MD, PhD Christopher A. Klebanoff, MD Kavita Y. Sarin, MD, PhD Leveraging patient-derived Clinical development of D.G. “Mitch” Mitchell Clinical organoid models to define next-generation T cell Investigator the molecular determinants of receptor (TCR)-based DAMON RUNYON Genetic contributions and metastatic regeneration with adoptive immunotherapies novel therapies for individuals Joan Massagué, PhD, Memorial for the treatment of patients with frequent basal cell cancer Sloan Kettering Cancer Center, with common epithelial with Jean Y. Tang, MD, PhD, New York malignancies with Michel CLINICAL INVESTIGATOR AWARD and Anthony E. Oro, MD, PhD, Sadelain, MD, PhD, and Larry Stanford University, Stanford Norton, MD, Memorial Sloan Catherine C. Smith, MD Kettering Cancer Center, CONTINUATION GRANT Richard Lumsden Foundation New York Clinical Investigator Defining structure, function and therapeutic impact of Illinois New York Heather L. Yeo, MD Use of mobile applications to oncogenic FLT3 mutations Jaehyuk Choi, MD, PhD Vinod P. Balachandran, MD* evaluate post surgical recovery with Neil P. Shah, MD, PhD, Development of novel Recombinant interleukin-33 in aging patients with GI cancer University of California, therapeutic strategies for immunotherapy for pancreatic with Manish A. Shah, MD, and San Francisco aggressive CTCL subtypes cancer with Steven D. Leach, Deborah L. Estrin, PhD, Weill with Stephen D. Miller, PhD, MD, and Jedd D. Wolchok, MD, Cornell Medicine, New York “SIMPLY PUT, MY DAMON RUNYON and Joan Guitart, MD, PhD, Memorial Sloan Kettering Northwestern University, Cancer Center, New York *Initial Year AWARD HAS SET MY CAREER Chicago Christopher E. Barbieri, MD, PhD ON A PATH FOR SUCCESS AS AN Missouri Subtype-specific modes of clinical and molecular ACADEMIC PHYSICIAN-SCIENTIST.” Vivek K. Arora, MD, PhD progression in prostate cancer Defining a targetable with Lewis C. Cantley, PhD, oncogenic dyad in bladder Weill Cornell Medicine, cancer with Lee Ratner, MD, New York PhD, Washington University, DAVID M. KURTZ, MD, PhD Saint Louis Piro Lito, MD, PhD* Modeling responses to targeted Damon Runyon Physician-Scientist ‘16-’19 ERK signaling inhibition at the single-cell level with Neal X. Stanford University Rosen, MD, PhD, and Charles M. Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York

36 37 DAMON RUNYON-RACHLEFF DAMON RUNYON-RACHLEFF INNOVATION AWARD COMMITTEE INNOVATION AWARD

CHAIR Ivan P. Maillard, MD, PhD Julie A. Segre, PhD Massachusetts Jan P. Schuemann, PhD Jason M. Sheltzer, PhD Vice Chief for Research, Chief and Senior Investigator, Using extreme dose rates Are cancers addicted to Lewis L. Lanier, PhD Liron Bar-Peled, PhD* Division of Hematology and Translational and Functional to protect healthy tissue in aneuploidy? at Cold Spring American Cancer Society Identification of redox Oncology Genomics Branch proton radiation therapy Harbor Laboratory, Cold Professor and Chair, vulnerabilities in genetically Professor of Medicine Head, Microbial Genomics at Massachusetts General Spring Harbor J. Michael Bishop, MD, defined cancers at Member, Abramson Cancer Section Hospital, Boston Distinguished Professor Massachusetts General Center National Human Genome Department of Microbiology Hospital, Boston Texas University of Pennsylvania Research Institute Alexandra-Chloé Villani, PhD and Immunology Perelman School of Medicine National Institutes of Health Deciphering the Achilles’ heel Xiaochun Li, PhD Leader, Cancer Immunology Michael E. Birnbaum, PhD* Investigations on Patched, PHILADELPHIA, PENNSYLVANIA BETHESDA, MARYLAND of cancer immunotherapy Program Decoding and reprogramming at Massachusetts General a tumor suppressor, and UCSF Helen Diller tumor-infiltrating T cells by Joshua T. Mendell, MD, PhD Stephen T. Smale, PhD Hospital, Boston its regulation in Hedgehog Family Comprehensive pMHC-targeted lentiviruses Professor and Vice Chair, Vice Dean for Research, pathway at University of Cancer Center at Massachusetts Institute of Department of Molecular David Geffen School of Texas Southwestern Medical University of California, Technology, Cambridge New York Biology Medicine at UCLA Center, Dallas San Francisco University of Texas Distinguished Professor, Michael E. Pacold, MD, PhD* SAN FRANCISCO, CALIFORNIA Brian B. Liau, PhD* Southwestern Medical Center Microbiology, Immunology Tracing molecular oxygen Utah Investigating allosteric Howard Hughes Medical and Molecular Genetics in pancreatic cancer at NYU Dafna Bar-Sagi, PhD mechanisms regulating DNA Gregory S. Ducker, PhD, and Institute Investigator Sherie L. and Donald G. Langone Health, New York Senior Vice President and methyltransferase enzymes at Kimberley J. Evason, MD, PhD* DALLAS, TEXAS Morrison Chair, Molecular Vice Dean for Science Harvard University, Cambridge Targeting phosphatidylcholine Immunology Elli Papaemmanuil, PhD* Chief Scientific Officer Joseph R. Osborne, MD, PhD metabolism in liver cancer University of California, Biological and clinical Saul J. Farber Professor of Chief, Nuclear Medicine and Joseph D. Mancias, MD, PhD using zebrafish at Huntsman Los Angeles implications of allelic Biochemistry and Molecular Identifying the pancreatic Cancer Institute at the Molecular Imaging LOS ANGELES, CALIFORNIA imbalances in clonal Pharmacology Director, Molecular Imaging tumor MHC-I ligandome in hematopoiesis and subsequent University of Utah, Salt Lake City Professor of Medicine Innovations Institute for Benjamin P. Tu, PhD response to ionizing radiation risk of therapy related leukemia

NYU Langone Health Inclusion University of Texas for combination radiation- at Memorial Sloan Kettering *Initial Year NEW YORK, NEW YORK Associate Professor of Southwestern immunotherapy at Dana-Farber Cancer Center, New York Radiology Presidential Scholar Cancer Institute, Boston Benjamin F. Cravatt, PhD New York-Presbyterian/Weill Martha Steiner Professorship Gilula Chair of Chemical Cornell Medicine in Medical Research Biology NEW YORK, NEW YORK W. W. Caruth, Jr. Scholar Professor, Chemistry in Biomedical Research DAMON RUNYON-RACHLEFF Nickolas Papadopoulos, PhD The Scripps Research Institute Professor, Biochemistry la jolla, california Professor of Oncology and University of Texas Pathology Southwestern Medical Center Tarun M. Kapoor, PhD Director of Translational INNOVATION AWARD DALLAS, TEXAS Pels Family Professor Genetics Head, Laboratory of Chemistry Ludwig Center for Cancer Founding Member and Cell Biology Genetics and Therapeutics STAGE 2 FUNDING The Rockefeller University Sidney Kimmel Comprehensive Ronald Levy, MD NEW YORK, NEW YORK Cancer Center Robert K. and Helen K. Summy Johns Hopkins University Professor Richard L. Klemke, PhD BALTIMORE, MARYLAND Stanford University School California Marcela V. Maus, MD, PhD Benjamin L. Martin, PhD, and Professor, Pathology, of Medicine Next-generation CAR T cells for David Q. Matus, PhD STANFORD, CALIFORNIA Rushika M. Perera, PhD Moores Cancer Center Theodora S. Ross, MD, PhD EGFRvIII-positive glioblastoma Cell cycle regulation of cellular Nadia’s Gift Foundation University of California, Vice President and Head at Massachusetts General behaviors associated with Innovator San Diego Translational Medicine Hospital, Boston cancer metastasis at Stony Mechanisms of cellular LA JOLLA, CALIFORNIA Merck and Company, Inc. Brook University, Stony Brook transformation at the single RAHWAY, NEW JERSEY New York organelle level at University of North Carolina California, San Francisco Arnold S. Han, MD, PhD* Precision T cell receptor-based Lawrence A. David, PhD, and Massachusetts cancer therapies at Columbia Anthony D. Sung, MD* University, New York Personalized prebiotics Eric S. Fischer, PhD* to optimize microbiota Novel mechanisms for small Amaia Lujambio, PhD* metabolism and improve molecule induced targeted Overcoming resistance to transplant outcomes at Duke degradation of RRM family anti-PD1 immunotherapy in University, Durham proteins at Dana-Farber Cancer hepatocellular carcinoma at Institute, Boston Icahn School of Medicine at *Initial Year Mount Sinai, New York

38 39 THANK YOU TO EVENTS & MEETINGS OUR DONORS

Your support this year enabled us to invest nearly $20 million in the next generation of leading scientists tackling the challenges of cancer research with bold new ideas and innovative technology. Since our founding in 1946, in VIRTUAL RUNYON 5K MOULIN ROUGE! THEATER BENEFIT partnership with donors across the nation, Damon Runyon Between August 24 and October 4, 2020, In November 2019, Damon Runyon Broadway has invested nearly $394 million and funded 3,826 more than 450 participants walked, ran, hiked, Tickets supporters enjoyed a reception and or biked a 5K along a course of their choice – conversation with Damon Runyon scientists young scientists. including many Damon Runyon scientists before taking in a performance of the Tony- across the nation who participated for the fi rst nominated musical Moulin Rouge! Our Theater time with friends, family, and labmates. The Benefi ts provide an opportunity for donors to Virtual Runyon 5K raised more than $60,000 experience an intimate evening with fellow AWARD SPONSORS for cancer research. patrons while learning more about the work Damon Runyon Broadway Tickets supports. We are grateful to our individual and corporate sponsors who have partnered with us to launch new programs or are funding one or more of our scientists. Donors can choose to fund scientists based on location, institution, research focus or cancer type, and the award can be named in recognition of their gift. For more information, visit: damonrunyon.org/ get-involved/sponsor

Award sponsors are listed on pages 42–44.

DAMON RUNYON BROADWAY TICKETS Damon Runyon Broadway Tickets offers premium seats to all of Broadway’s hit shows. We are grateful to the Shubert Organization, Nederlander Productions, Jujamcyn Theaters RAVEIS RIDE + WALK GOING VIRTUAL and Disney Theatrical Productions for making this program The William Raveis Charitable Fund hosted the Since March, we’ve been grateful for the possible. This year we’d like to extend special thanks to our fi fth annual Raveis Ride + Walk in September opportunity to connect with our community Premier Circle members for their ongoing support of our efforts 2019, raising $450,000 for Damon Runyon virtually through a series of webinars, symposia, to end cancer. We rely on the proceeds from Damon Runyon scientists. The family-friendly fundraiser attracts and celebrations. The Damon Runyon Fellows’ participants from Connecticut, New Jersey Retreat and Accelerating Cancer Cures Broadway Tickets to fund our brilliant scientists, and their and New York. We are grateful to everyone at symposia were both held virtually this fall, and loyalty has been crucial as we wait for Broadway’s reopening. William Raveis for their partnership and support in lieu of our Annual Breakfast, typically held in in raising more than $2.5 million for Damon the spring, Damon Runyon donors and friends TO LEARN MORE ABOUT DAMON RUNYON BROADWAY TICKETS AND PURCHASE GIFT CERTIFICATES, PLEASE VISIT Runyon since 2015. gathered online for A Virtual Toast to Science in DAMONRUNYON.ORG/BROADWAY. early December. We hope to resume in-person events in 2021.

40 41 SPONSORED AWARDS

We thank our individual, foundation, and corporate sponsors who have partnered LALLAGE FEAZEL WALL FELLOW* Geoffrey P. Dann, PhD Gregory P. Donaldson, PhD University of Pennsylvania The Rockefeller University with us to launch or provide continuing support for specific award programs. Laura V. Blanton, PhD Whitehead Institute for Biomedical Research Grace E. Kenney, PhD Ryan H. Moy, MD, PhD Harvard University Memorial Sloan Kettering Cancer Center DAMON RUNYON-RACHLEFF BERGER FOUNDATION FELLOW Yusong R. Guo, PhD LAYTON FAMILY FELLOW Janice M. Reimer, PhD INNOVATION AWARD The Rockefeller University Juhee Pae, PhD Jianjin Shi, PhD University of California, Ysbrand Nusse, PhD This award was established The Rockefeller University Stanford University San Diego University of Calgary Zhejian Ji, PhD thanks to the vision and Harvard Medical School generosity of Debbie and LORRAINE W. EGAN FELLOW* Mark R. Sullivan, PhD SUZANNE AND BOB WRIGHT CONNIE AND BOB LURIE FELLOW* FELLOW* Andy Rachleff. John C. Zinder, PhD Harvard T.H. Chan School of Whitney L. Johnson, PhD Chuan Li, PhD The Rockefeller University Public Health Tristan Wold Owens, PhD Dana Farber Cancer Institute NADIA’S GIFT FOUNDATION Stanford University University of California, San INNOVATOR MARION ABBE FELLOW* Shaogeng Steven Tang, PhD Francisco DALE F. AND BETTY Daniel H. Lin, PhD STAGE 2 FUNDING Stanford University School of ANN FREY FELLOW* Whitehead Institute for Nicholas M. Adams, PhD Rushika M. Perera, PhD Medicine WILLIAM RAVEIS CHARITABLE FUND Pragya Goel, PhD Biomedical Research New York University School of FELLOW University of California, Harvard Medical School Medicine Yunxiao Zhang, PhD San Francisco Jingchuan Luo, PhD Kunitoshi Chiba, PhD Scripps Research Institute DAVID M. LIVINGSTON, MD, FELLOW THE MARK FOUNDATION FOR Brigham and Women’s Hospital Whitehead Institute for CANCER RESEARCH FELLOWS CLINICAL INVESTIGATOR Tikvah K. Hayes, PhD Biomedical Research Caroline Bartman, PhD Xin Zhou, PhD *In perpetuity AWARD Dana-Farber Cancer Institute University of California, Colleen N. McLaughlin, PhD Princeton University San Francisco This award was initially DENNIS AND MARSHA Stanford University DAMON RUNYON-DALE F. established in partnership DAMMERMAN FELLOW* J. Brooks Crickard, PhD NATIONAL MAH JONGG FREY AWARD FOR with Eli Lilly and Company. In Columbia University LEAGUE FELLOW Marsha M. Hirschi, PhD Jose Reyes, PhD BREAKTHROUGH SCIENTISTS addition to the named awards, Scripps Research Institute Memorial Sloan Kettering Deepshika Ramanan, PhD CRIS CANCER FOUNDATION it is supported by Accelerating Cancer Center Jamie Lahvic, PhD Harvard Medical School BREAKTHROUGH SCIENTISTS Cancer Cures, a collaboration University of California, FAYEZ SAROFIM FELLOW* Ivana Gasic, Dr.Sc. between Damon Runyon and Esen Sefik, PhD Berkeley PHILIP O’BRYAN Shuo Han, PhD University of Geneva leading biopharmaceutical Yale School of Medicine MONTGOMERY, JR., MD, FELLOW companies. Stanford University School of Haoxin Li, PhD Medicine Nagarajan Nandagopal, PhD Iva A. Tchasovnikarova, PhD Jiao Sima, PhD Scripps Research Institute D.G. “MITCH” MITCHELL CLINICAL Harvard Medical School The Gurdon Institute at the University of California, INVESTIGATOR FRATERNAL ORDER OF University of Cambridge EAGLES FELLOW* Berkeley Katy Ong, PhD REBECCA RIDLEY KRY FELLOW* Kavita Y. Sarin, MD, PhD University of California, Victoria Hung, PhD Balint Z. Kacsoh, PhD Stanford University Tyler Starr, PhD Berkeley DAMON RUNYON-SOHN Stanford University School of University of Pennsylvania Fred Hutchinson Cancer Medicine PEDIATRIC CANCER RICHARD LUMSDEN FOUNDATION Ariana Peck, PhD Research Center THE RHEE FAMILY FELLOW FELLOWSHIP AWARD CLINICAL INVESTIGATOR California Institute of HOWARD HUGHES MEDICAL Technology Allison Didychuk, PhD This award program was Catherine C. Smith, MD INSTITUTE (HHMI) FELLOWS Christopher Wilson, PhD University of California, Harvard University University of California, launched in partnership with San Francisco Junhong Choi, PhD Jonathan G. Van Vranken, PhD Berkeley the generous support of the University of Washington Yuxiang Zhang, MD, PhD Harvard Medical School Sohn Conference Foundation. ROBERT A. SWANSON Boston Children’s Hospital FAMILY FELLOW FELLOWSHIP AWARD Yuan Gao, PhD Lexy von Diezmann, PhD CANDY AND WILLIAM RAVEIS FELLOW The following awards are Harvard Medical School Ge Zheng, PhD University of Utah School Kouki Touhara, PhD funded by donors who have Boston Children’s Hospital of Medicine University of California, San Jessie A. Brown, PhD Francisco generously endowed an award Stephanie Gates, PhD Columbia-Presbyterian Medical in perpetuity or sponsored an University of California, ILLINI 4000 FELLOW Jing Lin Xie, PhD Center Berkeley Stanford University School ROBERT BLACK FELLOWS individual Fellow. Daniel J. Blair, PhD of Medicine University of Illinois at Urbana- Tess C. Branon, PhD AGBT - ELAINE R. MARDIS Rachel S. Greenberg, PhD Champaign University of California, FELLOWSHIP IN CANCER GENOMICS Harvard Medical School MERCK FELLOWS Berkeley Steven W.M. Crossley, PhD KENNETH G. AND ELAINE A. Robert S. Banh, PhD University of California, Keelan Z. Guiley, PhD LANGONE FELLOW* New York University School Elizabeth A. Costa, PhD University of California, San Berkeley Eric E. Gardner, PharmD, PhD of Medicine Whitehead Institute for Francisco Weill Cornell Medicine Biomedical Research

42 43 SPONSORED AWARDS CONTINUED OUR CONTRIBUTORS

DAMON RUNYON-SOHN PEDIATRIC DAMON RUNYON PHYSICIAN- DAMON RUNYON-JAKE CANCER FELLOWS SUPPORTED The Damon Runyon Cancer Research Foundation acknowledges the generosity of the SCIENTIST TRAINING AWARD WETCHLER AWARD FOR BY THE SOHN CONFERENCE many donors who supported our brilliant researchers through gifts to the Foundation from FOUNDATION This award was established PEDIATRIC INNOVATION Adam D. Durbin, MD, PhD thanks to the generosity of This $5,000 award is named in July 1, 2019 to June 30, 2020. Individuals whose lifetime giving is $100,000 or more are Dana-Farber Cancer Institute Damon Runyon Board Members honor of Jake Wetchler, who listed in bold, and those whose lifetime giving exceeds $1 million are listed in blue. We Leon G. Cooperman and died at age 20 after a heroic Kiara C. Eldred, PhD Michael L. Gordon. fight against two different are especially grateful to these extraordinarily generous and committed donors. Washington University cancers. THE BEN AND CATHERINE IVY FOUNDATION PHYSICIAN-SCIENTIST Anand G. Patel, MD, PhD Marissa Rashkovan, PhD St. Jude Children’s Research Elisa A. Aquilanti, MD Columbia University Medical Hospital Dana-Farber Cancer Institute Center $1,000,000+ Connie and Bob Lurie The Erlbaum Family The Bakewell Foundation MetLife Foundation Illini 4000 Zulekha A. Qadeer, PhD GORDON FAMILY PHYSICIAN- *In perpetuity D.G. Mitchell Morana Jovan-Embiricos, PhD SCIENTIST The Mark Foundation for University of California, Cancer Research Nadia’s Gift Foundation Katherine and Henry Mannix III San Francisco Jonathan C. Dudley, MD Sohn Conference Foundation Debbie and Andy Rachleff Sandy and David Marshall The Johns Hopkins University William Raveis Charitable Susan Riley and John Marissa Rashkovan, PhD School of Medicine Fund McKeown $500,000 - $999,999 Columbia University Carole Middleton Fund Medical Center LEE COOPERMAN Anonymous PHYSICIAN-SCIENTIST $50,000 - $99,999 Gordon H. and Karen M. William K. Bowes, Jr. Millner Family Foundation Anonymous Jay F. Sarthy, MD, PhD John R. Ferrarone, MD Foundation The Bruce Robert Reid Family Sol and Margaret Berger Weill Cornell Medicine Michael L. Gordon Foundation Fred Hutchinson Cancer Foundation Research Center Howard Hughes Medical The Rogers Charitable Fund CRIS Cancer Foundation THE MARK FOUNDATION FOR Institute The Rosenfield & Glassman CANCER RESEARCH PHYSICIAN- The Samuel Freeman Merck & Co., Inc. Foundation Kathryn R. Taylor, PhD SCIENTIST Charitable Trust Stanford University School Karen D. Seitz Steve Hayden of Medicine Natalie Vokes, MD Monika Stengert $100,000 - $499,999 Hettinger Foundation Dana-Farber Cancer Institute Nathaniel S. Turner V Elaine M. Addis Revocable The Layton Family Fund Peng Wu, MD, PhD Laura and Peter Van Camp WILLIAM RAVEIS CHARITABLE FUND Trust Mary and Eugene F. Murphy Stanford University School of PHYSICIAN-SCIENTIST Medicine Velma M. Anderson Trust National Mah Jongg League Lillian M. Guenther, MD Terry and David Beirne Foundation $10,000 - $24,999 Dana-Farber Cancer Institute Robert Black Charitable Select Equity Group Anonymous (2) Foundation Foundation Baupost Group, LLC Edith C. Blum Foundation Judy C. Swanson Echlin Foundation Estate of Adrienne and Harry Anita Tarr Turk Fund for Chamberlain Breast Cancer Research Lorraine and Bill Egan Deborah J. Coleman and Varelas Family Fund Ensemble Capital, LLC Timothy W. Diggins Edward P. Evans Foundation The Leon and Toby Cooperman $25,000 - $49,999 Erica Evans Gioffre and “DAMON RUNYON HAS A PROVEN TRACK RECORD Family Foundation Michael Gioffre Genentech, Inc. Angelo Gordon The Fine and Greenwald OF SUPPORTING SCIENTISTS WHEN THE WATERS The Genome Partnership, Inc. Judy Hart Angelo Foundation, Inc. The Ben and Catherine Ivy Anonymous (2) Joan Lobis Brown and ARE STILL AND HAS PROVEN THEY CAN CONTINUE Foundation Barthold Family Foundation Jeremy Grayzel Sherry and Alan Leventhal Beacon Capital Partners, LLC Sharon and Scott Greenstein THEIR MISSION WHEN THE TIMES ARE MORE Family Foundation Robyn and Tony Coles, MD Valerie and Jay Ireland Richard A. Lumsden Estate of Rita Eisenberg William G. Kaelin, Jr., MD CHALLENGING.” Foundation Steven A. Kandarian

SELECT EQUITY GROUP

Corporate Donor *Our donor lists are checked carefully. However, if you have any corrections or questions, please call us at 877.722.6237. The pledge amount is listed in the year the pledge is made. In subsequent years, pledge payments are listed.

44 45 OUR CONTRIBUTORS CONTINUED

“I LOVE HOW DAMON RUNYON BRINGS SOME $1,000 - $4,999 Thomas Carrajat Camille and Stephen Fish Carolyn Aller Charina Foundation Nancy A. Federspiel, PhD, and OF THE SMARTEST MINDS TO THE TABLE TO Robert F. Fisher, PhD Sharman and David Altshuler Judy Chase ATTRACT TALENTED SCIENTISTS, VET THEIR Advised Fund Philip J. Clark Jill and Mark Fishman Anonymous (6) Cynthia and Jay L. Cohan David Fleishhacker IDEAS, AND STAY INVOLVED AS MENTORS The Apple Lane Foundation Charitable Gift Fund Donna Flower Glant Cohen Sally Fonner AFTER AWARDS ARE GRANTED.” Susannah Bailin Arnold and Mary Jo Barnett Harvey Coleman Robert Forrest, Jr. Philanthropic Foundation Cara and Brian Cook Kelly and Buck French Richard Barnett Howard J. Cooperman Mary Ann Frenzel Julie and Roger Baumann Teresa and Jim Copenhaver Elaine V. Fuchs, PhD, and David Hansen NAT TURNER Ann and Thomas Berger Victor C. Costa Sandye Berger Elinor and Michael Crames The Garthwait Family Fund Founder and CEO, Flatiron Health Jordan Berman Brenda L. Crane Nancy and Richard B. Gaynor, MD Donald P. Biek, PhD Kristine and Jonathan Crawford Nancy and Charles Geschke Maryann and Thomas Giaimo Damon Runyon Board Member Eugenie and Robert Birch Lawrence H. David BLL Foundation Peggy and Phil DeZwirek Jeffrey W. Glazer Foundation Kaoru and Chip Block Gayle and John Dilley Alfred S. Glazier William Boeh Russell Dorsky Ken Globus Donna Boone James Dow Marc. E. Goldberg June and Thomas Bracken Donald Dreyfus Goldie Anna Charitable Trust Janet and Richard Bruce Nancy Dubow Goldstone Fund, Inc. The Lichtenberger Foundation Dorothy D’Amato Lawrence Jordan Judy Buechner Advised Fund Carol Dubron-Witlin Martha and Todd R. Golub, MD The Luppe And Paula Luppen Jane and Larry Droppa Angela and Noah Knauf Ann and Frank Bumstead Monica Duvall, MD, and Daniel Elizabeth A. Gray Family Foundation Estate of Edward and Bozena The Edward F. Limato Foundation Suzanne and Steven J. DiLella Terri Grodzicker, PhD Julie and Gerald Marshall Etnyre Clare and Kenneth Livak, PhD Burakoff, MD Carol and Dexter Earle Eleanor Gross Paula Ryan, MD, PhD, and The Ettl Family Philanthropic Emily and David Livingston, MD Jack J. Burke Marilyn and Erwin Ezzes Lisa C. Hargrove Michael Seiden, MD, PhD Fund Marble Fund, Inc. Nancy S. Calcagnini Fund Phyllis Feigenbaum Kristy and Robert L. Harteveldt Henry J. and Kathleen Singer Elizabeth Fazzino McKesson Corporation Roberta Fine Happy G. Hawn Family Foundation Dorothy Carnegie-Shillinglaw, MD The Frances and Jeffrey Fisher Jami W. McKeon The Richard C. and Theresa P. Charitable Foundation Martin Metz Smith Memorial Fund Margaret and James Funicello The Leo Model Foundation, Inc. The Linda B. and Howard S. General Electric Foundation Jody and John Myers Stern Family Foundation Brinda Govindan, PhD, and Cynthia F. Sulzberger and Bhaskar Ghosh, PhD Shelly M. Payne, PhD Steven B. Green Steve Goldberg Emily and Michael Repperger The Symonds Foundation Mignon and James Groch Sylvia and Norman Samet Carol and Lee Tesconi Heitman, LLC Suzy Sang Shechtman Joan and Robert M. Hess Karen and Harvey Silverman $5,000 - $9,999 Marion Hindin Stewart Senter, Inc. Barbara Lieb Baumstein Estate of Irma T. Hirschl Carole and Jerry Turk Family Philanthropic Fund The Howard Bayne Fund Solange and Michael Hommel Bernhard H. Van Lengerich, PhD Jill C. Bee Celia Pohani and Daniel Huber The Wasserman Foundation Isabel and Steven Berg Lori and Wayne Hummel Barbara and Robert C. Young, MD Burlingame Foundation Andre Hunter Estate of Laurelia M. Clifford Scott R. Isdaner Paula and Martin Cohen J.I. Foundation, Inc. Jane and Alan Cornell The Robert D. & Phyllis A. Jaffee Family Foundation

46 47 OUR CONTRIBUTORS CONTINUED

Donald Herdrich Jennifer Madden Louis Popowsky The Harvey Silverman Linda and Edward Wacks Virginia Hintermeister The Billi Marcus Foundation Elizabeth Portland and Thomas Foundation Robert T. Waldbauer, Jr. Lisa Gross and Richard August Mattheyses Fund Toce Patricia Silverstein Waterfall Family Foundation Hoffman Helen and Tom May Isabel and In Sik Rhee Jeff Smith Michele and Donald Weeden Clair Howey Theodore and Karin Mayer Jane and D. Paul Rittmaster Estate of Lidie Anne Smith Laura and Henry Weil Kirsten and Kevin Hungate Family Foundation Jean and Sir Richard Estate of Mildred A. Smith Joanne and Arthur Weinbach Julia R. Johnson Pells Mayton Foundation, Inc. Roberts, PhD Philippe Soriano, DSc, PhD Vicki and Victor Weinstein Robert Kaplan Christopher McGarrigal Mary Beth Roche Todd Standard David and Candace Weir Edith and Aaron Kaufman David McIntosh Karen and Gary Rockhold Keren and Alex Stankevich Foundation Michael Keeley Christine S. McKiernan Elizabeth Roddin Judith and James Studer Carol Windsor and James A. Stanley Keys McKinsey & Company, Inc. The Roxe Foundation Mark Stueve Wells, PhD Jennifer and James H. Colleen and Michael W. Kimberly Rubin Polly Tam and Hsien-Chung Ariana Whitson Kimenker McMahon Lauren Ruderfer Woo Janet M. Widra, PhD, and Alan Robert King The Messinger Foundation, Inc. Daniel Sack Matt Taylor Widra Douglas Kinney Fred Middleton Linda and Donald Sage Karen and Sanford Teplitzky Arun P. Wiita, MD, PhD Lee P. Klingenstein I. George Miller, MD Geri Saltzman Patricia and J. Ronald Vincent Wilczynski Frank T. Koelble Laura Miller Ilene Sands Terwilliger Winfield Foundation Sandra Krause Suzy, Nancy, and Carol Minkoff Lief Sannen, DDS Tullia Lindsten, MD, PhD, and Jami McLaughlin and Owen N. The Krimendahl/Saint-Amand Charitable Fund Albert Santos Craig Thompson, MD Witte, MD Foundation Patty Hogan and Sanford Richard Saperstein Jennifer Toll Kim Zelnick Carol Kripke Morhouse Linda and Jerry Saslow Dina Treanor and Jeffrey Taschler Jill Kusmirek David Moskowitz, PhD David G. Schwartz Jeremy Lack, PhD Sandra and Eric Mudafort Marvin C. Schwartz Barbara Landau John E. Murphy, PhD Carla and Richard Scudellari Ellen S. Lane Herbert Natof, MD Robert J. Seifer Cancer Janice R. Lane Neu Foundation of California, Inc. Research Foundation “I BELIEVE IN FUNDING RESEARCH AND SCIENCE THAT CAN Kim Le Sonia and Phillip Newmark, PhD Marianne and William Suzie Lee William O’Boyle Sellers, MD ULTIMATELY AFFECT PEOPLE’S LIVES. DAMON RUNYON LGBTQ Libertarian Fund Jeffrey M. Ostrove, PhD Ethel G. Sensenig Dan R. Littman, MD, PhD Donna and Chris Paisley Abraham I. & Jean Sherr UNIQUELY PROVIDES ME EVERY OPPORTUNITY TO BECOME Mary and Fred Litwin Gladys and John Parker Foundation, Inc. Michael Lorusso Stephen Patterson Rita Sherr PERSONALLY INVOLVED IN ALL ASPECTS OF SUPPORT.” Frank E. and Miriam Loveman Kathryn M. Kent and Robert D. Shmerler Foundation, Inc. Foundation, Inc. Patton Fay and William Shutzer Alex Lyakhov The Jay and Carolyn Paxton The Sidewater Family Abigail and Case Lynch Fund Foundation, Inc. Carol MacCorkle Joseph Piorkowski Joseph M. Siegman Family JUDY SWANSON Foundation Barbara Macklowe Vickie and Rahn Pitzer Damon Runyon Board Member

48 49 ACCELERATING CANCER CURES BROADWAY PREMIER CIRCLE

Accelerating Cancer Cures is supported by leading biopharmaceutical companies The Broadway Premier Circle is a group of loyal Damon Runyon Broadway Tickets that are committed to fi nding new cures for cancer. Thank you to Genentech, Merck, customers who have made a special donation in support of cancer research. The AbbVie, and Amgen for partnering with us to support the Damon Runyon Clinical Premier Circle offers members priority access to tickets and other benefi ts. Investigator Award. David Altshuler Scott R. Isdaner Joseph D. Roxe In conjunction with this initiative, each year the Accelerating Cancer Cures Research Anonymous Robert Kaplan Kimberly Rubin Symposium brings together our Clinical Investigators with industry leaders to foster Susannah Bailin Jennifer and James H. Sylvia and Norman Samet Barbara Lieb Baumstein Kimenker Ilene Sands communication and collaboration helping speed progress against cancer. Jill C. Bee Dorothy R. Davies and Jeremy Linda and Jerry Saslow Janet and Richard Bruce R. Kramer Rita Sherr Ann and Frank Bumstead Ellen S. Lane Shmerler Foundation, Inc. Philip J. Clark Stephen M. Levy The Sidewater Family Samuel T. Cohen The Edward F. Limato Foundation, Inc. Foundation Dorothy D’Amato Karen and Harvey Silverman Susan and Martin Lipton Jane and Larry Droppa Charlotte and John S. Suhler Clare and Kenneth Livak, PhD Marian and Robert Ettl Jennifer Toll Abigail and Case Lynch Jill and Mark Fishman Linda and Edward Wacks William M. Matthews Mary Ann Frenzel Judith and Peter Wasserman Jami W. McKeon Joan Lobis Brown and Jeremy Vicki and Victor Weinstein Grayzel Colleen and Michael W. Janet M. Widra, PhD, and Alan McMahon Mignon and James Groch Widra Agnes Peelle Eleanor Gross Jami McLaughlin and Owen N. Joseph Piorkowski “NO SINGLE ELEMENT OF PHARMA, ACADEMIA, SMALL BIOTECH, Donald Herdrich Witte, MD Judy Rosenblum Barbara and Robert C. Young, MD FUNDERS, VENTURE CAPITAL, OR THE NIH IS SUFFICIENT TO DO Andre Hunter THE DIFFICULT JOB OF UNDERSTANDING THE BIOLOGY, FINDING THE TARGETS, MAKING THE MOLECULES, AND THEN DEVELOPING THEM CLINICALLY. IT TAKES ALL COMPONENTS OF THE DISCOVERY SOCIETY BIOMEDICAL ECOSYSTEM. ONE OF THE GREAT STRENGTHS OF DAMON RUNYON IS ITS ROLE IN FORGING CONNECTIONS WITH REALLY SMART SCIENTISTS AT A FORMATIVE PART OF THEIR Discovery Society members are valued supporters who have provided for the Damon CAREERS. IT WILL TAKE A DENSE SET OF THESE CONNECTIONS Runyon Cancer Research Foundation through future planned gifts. These donations TO BRIDGE THE GAP FROM THE POTENTIAL THAT SCIENCE CAN provide a vital source of support and fuel future breakthroughs against cancer. BRING TO THE ACTUAL DELIVERABLES OF WHAT WE ALL WANT, Mary Jo and Arnold Barnett Nancy and Richard B. Gaynor, MD Debra L. and Ronald E. Parr WHICH IS BETTER MEDICINES FOR PATIENTS.” Judy Chase Rick J. Govern Lynne and Rick Robinson Paula and Martin Cohen Georgia M. and William C. Hines Seymour Rosenheck Toby and Leon Cooperman Rebecca R. Kry Esther E. and Herbert Schwartz Ann K. Cote Linda B. Lloyd and Lewis L. William Scroggins NICK HAINING, BM, BCH Anne C. Burkholder, PhD, and Lanier, PhD Phoebe Showers Stephen P. Eisenberg, PhD Catherine and Leo LoFrisco Wallace Specter Vice President, Phyllis Farleigh Thomas J. Lukas, PhD Carol H. Stix Discovery Oncology Nancy A. Federspiel, PhD, and D.G. Mitchell Rose Vaccariello Merck Robert F. Fisher, PhD Diane Roberto Jacqueline and Arthur Walker Mary Ann Frenzel

50 51 FINANCIAL SUMMARY WAYS FISCAL YEAR 2020 TO GIVE As in previous years, the fi nancial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2020.

For our complete audited fi nancial statements, please visit our website at damonrunyon.org ONLINE damonrunyon.org/donate

TOTAL OPERATING EXPENSES TOTAL REVENUE PHONE 1.877.7CANCER or 1.877.722.6237 9 am–5 pm ET, Monday to Friday

MAIL $24 $24 One Exchange Plaza, 55 Broadway, Suite 302 MILLION MILLION New York, NY 10006

ESTATE PLANNING Visit our website for more information: Award Programs 87.6% Investment Return 28.6% damonrunyon.org/get-involved Fundraising 9.1% Contributions 63.2% General Administration 3.3% Misc. Income 2.8% Bequests & Trusts 4.6% Damon Runyon Broadway Tickets 0.8% DAMON RUNYON BROADWAY TICKETS Damon Runyon Broadway Tickets offers Broadway’s best seats and the opportunity to support cutting-edge cancer research at the same time. Orchestra seats are 2019 2020 available for even the most popular shows. SUMMARY OF Total Assets $150,535,887 $148,107,071 Join our Premier Circle to Our Gift Certifi cates are Call us for tickets at BALANCE SHEETS Total Liabilities $35,517,843 $35,521,826 enjoy benefi ts like priority perfect for holiday gifts, as 212.455.0550 between Total Net Assets $115,018,044 $112,585,245 access to tickets before well as birthdays, anniversaries, 9 am–5 pm ET, Monday they go on sale each month, or any occasion—a fun night to Friday. Purchase tickets and more. and a meaningful gift. online at damonrunyon.org/ broadway 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS. We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

52 53 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

54